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11p15	  LOM	   	   loss	  of	  methylation	  at	  chromosome	  11p15	  
3-­‐M	  syndrome	   a	  syndrome	  named	  after	  researchers	  Miller,	  McKusick	  and	  
Malvaux	  
AGA	   	   	   appropriate	  for	  gestational	  age	  
AGPAT5	  	   	   1-­‐acylglycerol-­‐3-­‐phosphate	  O-­‐acyltransferase	  5	  
AS	   	   	   Angelman	  syndrome	  
BMI	   	   	   body	  mass	  index	  
BWS	   	   	   Beckwith-­‐Wiedemann	  syndrome	  
CARD11	   	   caspase	  recruitment	  domain	  family	  member	  11	  
cDNA	   	   	   complementary	  DNA	  
CDKN1C	   	   cyclin	  dependent	  kinase	  inhibitor	  1C	  
CF	   	   	   cystic	  fibrosis	  
CGI	   	   	   CpG	  island	  
CNTNAP2	  	   	   contactin	  associated	  protein	  like	  2	  
CNV	   	   	   copy	  number	  variation	  
COL1A2	   	   collagen	  type	  I	  alpha	  2	  chain	  
CpG	   	   	   a	  site	  in	  the	  DNA	  sequence	  where	  a	  cytosine	  (C)	  is	  followed	  	  
	   	   	   by	  a	  guanine	  (G)	  nucleotide	  
CSRP1	  	   	   	   cysteine	  and	  glycine	  rich	  protein	  1	  
CTCF	   	   	   CCCTC-­‐binding	  factor	  
Da	   	   	   Dalton	  
DMR	   	   	   differentially	  methylated	  region	  
DNA	   	   	   deoxyribonucleic	  acid	  
DNAse	  I	   	   deoxyribonuclease	  I	  
DNMT	   	   	   DNA	  methyltransferase	  
DNMT1	   	   DNA	  methyltransferase	  1	  
DNMT3A	   	   DNA	  methyltransferase	  3A	  
DNMT3B	   	   DNA	  methyltransferase	  3B	  
dNTP	   	   	   deoxyribonucleotide	  triphosphate	  
EZH2	   	   	   Enhancer	  of	  Zeste	  Homolog	  2	  
FRMD6	  	   	   FERM	  domain	  containing	  6	  
GH	   	   	   growth	  hormone	  
GLI3	   	   	   GLI	  family	  zinc	  finger	  3	  
GNAS	   guanine	  nucleotide	  binding	  protein	  alpha	  stimulating	  complex	  
locus	  
GPC5	  	   glypican	  5	  
GPC6	  	   glypican	  6	  
GR	   glucocorticoid	  receptor	  
GRB10	   	   	   growth	  factor	  receptor	  bound	  protein	  10	  
GWAS	   	   	   genome-­‐wide	  association	  study	  
H19	   	   	   H19,	  imprinted	  maternally	  expressed	  transcript	  
H19/IGF2:IG-­‐DMR	   H19-­‐IGF2	  intergenic	  differentially	  methylated	  region	  
HIL	   	   	   hypomethylation	  of	  multiple	  imprinted	  loci	  
HOX	  genes	   	   a	  subset	  of	  homeobox-­‐containing	  genes	  that	  regulate	  
	   	   	   the	  anterior-­‐posterior	  patterning	  of	  an	  embryo	  
HOXA4	   	   	   homeobox	  A4	  
HTR5A	   	   	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  5A	  
IC	   	   	   imprinting	  center	  
ICR	   	   	   imprinting	  control	  region	  
IGB	   	   	   integrated	  genome	  browser	  
	   9	  
IGF1	   	   	   insulin-­‐like	  growth	  factor	  1	  
IGF1R	   	   	   insulin-­‐like	  growth	  factor	  1	  receptor	  
IGF2	   	   	   insulin-­‐like	  growth	  factor	  2	  
Igf2r	   	   	   insulin-­‐like	  growth	  factor	  2	  receptor	  
IMAGe	   intrauterine	  growth	  restriction,	  metaphyseal	  dysplasia,	  
congenital	  adrenal	  hypoplasia	  and	  genital	  anomalies	  
ISS	   	   	   idiopathic	  short	  stature	  
ITGB8	  	   	   	   integrin	  subunit	  beta	  8	  
IUGR	   	   	   intrauterine	  growth	  restriction	  
Kcnq1	   	   	   potassium	  voltage-­‐gated	  channel,	  subfamily	  Q,	  member	  1	  
Kcnq1ot1	   	   Kcnq1	  overlapping	  transcript	  1	  
KOS	   	   	   Kagami-­‐Ogata	  syndrome	  
lncRNA	  	   	   long	  non-­‐coding	  RNA	  
LOI	   	   	   loss	  of	  imprinting	  
LOM	   	   	   loss	  of	  methylation	  
MAD1L1	   	   mitotic	  arrest	  deficient	  1	  like	  1	  
MALDI-­‐TOF	  MS	   matrix	  assisted	  laser	  desorption/ionization	  –	  time	  of	  flight	  mass	  
spectrometry	  
MBCS	   Mulchandani-­‐Bhoj-­‐Conlin	  syndrome	   	   	  
MEST	   	   	   mesoderm	  specific	  transcript	  
MESTIT1	   	   MEST	  intronic	  transcript	  1,	  antisense	  RNA	  
MHS	   	   	   multilocus	  hypomethylation	  syndrome	  
MLH	   	   	   multilocus	  hypomethylation	  
MLID	   	   	   multi-­‐locus	  imprinting	  disturbance	  
MLMD	   	   	   multilocus	  methylation	  defects	  
mRNA	   	   	   messenger	  RNA	  
Mulibrey	  nanism	   MUscle,	  LIver,	  BRain,	  EYes	  nanism	  
ncRNA	   	   	   non-­‐coding	  RNA	  
NH-­‐CSS	  	   	   Netchine-­‐Harbison	  clinical	  scoring	  system	   	   	  
PCR	   	   	   polymerase	  chain	  reaction	  
PEG3	   	   	   paternally	  expressed	  3	  
PEG10	   	   	   paternally	  expressed	  10	  
PHLDA2	   	   pleckstrin	  homology	  like	  domain	  family	  A	  member	  2	  
PHP1B	  	  	   	   pseudohypoparathyroidism	  type	  1b	  
PLAGL1/HYMAI	   PLAG1	  like	  zinc	  finger	  1/hydatidiform	  mole	  associated	  and	  
imprinted	  
PON1	   	   	   paraoxonase	  1	  
POU6F1	  	   	   POU	  class	  6	  homeobox	  1	  
PWS	   	   	   Prader-­‐Willi	  syndrome	  
PRR15	   	   	   proline	  rich	  15	  
qPCR	   	   	   quantitative	  real-­‐time	  polymerase	  chain	  reaction	  
RARRES2	   	   retinoic	  acid	  receptor	  responder	  2	  
RERG	  	   	   	   RAS	  like	  estrogen	  regulated	  growth	  inhibitor	  
RFLP	   	   	   restriction	  fragment	  length	  polymorphism	  
RIN	   	   	   RNA	  integrity	  number	  
RNA	   	   	   ribonucleic	  acid	  
RPS2P32	   	   ribosomal	  protein	  S2	  pseudogene	  
SD	   	   	   standard	  deviation	  
SGA	   	   	   small	  for	  gestational	  age	  
SGR	   	   	   severe	  growth	  restriction	  of	  unknown	  etiology	  
SGCE	   	   	   sarcoglycan	  epsilon	  
SH2B2	   	   	   SH2B	  adaptor	  protein	  2	  
SH3MD4	  	   	   SH3	  domain	  containing	  ring	  finger	  3	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SHORT	   short	  stature,	  hyperextensibility	  of	  joints,	  ocular	  depression,	  
Rieger	  anomaly	  and	  teething	  delay	  
SHOX	   	   	   short	  stature	  homeobox	  
SNP	   	   	   single	  nucleotide	  polymorphism	  
SOX21	  	   	   	   SRY-­‐box	  21	  
SPOCK1	  	   SPARC	  (osteonectin),	  cwcv	  and	  kazal	  like	  domains	  proteoglycan	  
1	  
SRS	   	   	   Silver-­‐Russell	  Syndrome	  
Sty	  I	   a	  restriction	  enzyme	  purified	  from	  E.	  coli	  WA921/pST27	  hsd+	  
SVOPL	   	   	   SVOP	  like	  
TFCP2	  	   	   	   transcription	  factor	  CP2	  
TFBS	   	   	   transcription	  factor	  binding	  site	  
TNDM	   	   	   transient	  neonatal	  diabetes	  mellitus	  
TS	   	   	   Temple	  syndrome	  
TSS	   	   	   transcription	  start	  site	  
ueSRS	   	   	   unexplained	  Silver-­‐Russell	  Syndrome	  
UPD	   	   	   uniparental	  disomy	  
UPD(7)mat	   	   maternal	  uniparental	  disomy	  of	  chromosome	  7	  
UPD(7)pat	   	   paternal	  uniparental	  disomy	  of	  chromosome	  7	   	   	  
VLBW	   very	  low	  birth	  weight	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ABSTRACT	  	  
	  
A	  large	  part	  of	  the	  genetic	  and	  epigenetic	  changes	  contributing	  to	  human	  height	  
and	  growth	  remain	  unknown.	  Silver-­‐Russell	  syndrome	  (SRS)	  is	  a	  rare	  human	  
growth	  disorder,	  where	  maternal	  uniparental	  disomy	  of	  chromosome	  7	  
[UPD(7)mat]	  and	  loss	  of	  methylation	  at	  11p15	  (11p15	  LOM)	  are	  the	  two	  major	  
findings.	  However,	  a	  substantial	  proportion	  of	  the	  SRS	  patients	  remain	  without	  a	  
molecular	  diagnosis.	  SRS	  is	  caused	  by	  a	  disturbance	  of	  imprinted	  genes	  that	  are	  
expressed	  solely	  or	  predominantly	  from	  one	  parent	  and	  are	  important	  for	  
growth	  and	  development.	  Imprinted	  genes	  may	  also	  be	  especially	  susceptible	  to	  
environmental	  factors,	  which	  can	  cause	  persistent	  changes	  in	  methylation	  
patterns	  and	  affect	  development	  of	  adult-­‐onset	  diseases.	  	  
	  
This	  thesis	  aims	  to	  explore	  new	  genetic	  and	  epigenetic	  changes	  in	  SRS,	  as	  well	  as	  
epigenetic	  changes	  of	  imprinted	  genes	  in	  growth-­‐restricted	  children,	  children	  of	  
normal	  growth	  and	  individuals	  born	  pre-­‐term.	  	  
	  
In	  Study	  I,	  genomic	  structural	  variation	  of	  22	  SRS	  patients	  was	  studied	  with	  the	  
Affymetrix	  250K	  Sty	  microarray.	  Several	  copy	  number	  changes	  were	  found,	  
including	  a	  heterozygous	  deletion	  of	  15q26.3	  including	  the	  insulin-­‐like	  growth	  
factor	  1	  receptor	  (IGF1R)	  gene.	  	  
	  
In	  Study	  II,	  CpGs	  in	  the	  insulin-­‐like	  growth	  factor	  2	  (IGF2)	  gene	  (located	  in	  the	  
11p15	  region)	  were	  tested	  in	  pre-­‐term	  and	  very	  low	  birth	  weight	  born	  
individuals	  with	  elevated	  levels	  of	  cardiovascular	  risk	  factors.	  DNA	  methylation	  
changes	  were	  found	  in	  one	  CpG	  site	  of	  the	  pre-­‐term	  born	  individuals	  compared	  
to	  controls.	  	  
	  
In	  Study	  III,	  genome	  wide	  comparisons	  between	  the	  DNA	  methylation	  levels	  of	  
SRS	  patients	  that	  have	  UPD(7)mat,	  controls,	  and	  an	  individual	  with	  paternal	  
uniparental	  disomy	  of	  chromosome	  7	  [UPD(7)pat]	  were	  done.	  DNA	  methylation	  
was	  studied	  using	  the	  Illumina	  Infinium	  HumanMethylation450K	  BeadChip	  
technology,	  which	  is	  capable	  of	  measuring	  methylation	  level	  of	  more	  than	  450	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000	  CpG	  sites	  across	  the	  genome.	  The	  study	  provided	  new	  information	  on	  the	  
DNA	  methylation	  landscape	  of	  chromosome	  7,	  suggesting	  new	  differentially	  
methylated	  regions	  (DMRs)	  and	  imprinted	  genes.	  	  
	  
In	  Study	  IV,	  DNA	  methylation	  levels	  were	  compared	  between	  three	  different	  
subgroups	  of	  SRS:	  SRS	  with	  UPD(7)mat,	  SRS	  with	  11p15	  LOM	  and	  clinical	  SRS	  
without	  a	  known	  molecular	  etiology.	  The	  promoter	  region	  of	  homeobox	  A4	  
(HOXA4)	  gene	  was	  found	  hypomethylated	  in	  all	  of	  the	  subgroups	  of	  SRS.	  This	  
region	  was	  subsequently	  tested	  in	  other	  severely	  growth-­‐restricted	  patients	  and	  
was	  found	  hypomethylated.	  Additionally,	  the	  methylation	  level	  of	  the	  HOXA4	  
promoter	  region	  was	  found	  to	  be	  associated	  with	  the	  height	  of	  school-­‐aged	  
children,	  suggesting	  that	  HOXA4	  plays	  a	  role	  not	  only	  in	  SRS	  but	  also	  in	  the	  
regulation	  of	  height	  in	  general.	  
	  
These	  studies	  found	  molecular	  changes	  in	  SRS,	  new	  differentially	  methylated	  
regions	  in	  chromosome	  7	  and	  epigenetic	  findings	  potentially	  relevant	  for	  
regulation	  of	  human	  growth.	  The	  findings	  provide	  potential	  targets	  for	  further	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INTRODUCTION	  	  
	  
Human	  height	  is	  a	  complex	  trait	  with	  high	  heritability.	  As	  demonstrated	  by	  large	  
genome-­‐wide	  association	  studies	  (GWAS),	  human	  height	  is	  regulated	  by	  
hundreds	  of	  genes,	  with	  each	  locus	  typically	  explaining	  a	  small	  proportion	  of	  the	  
variation.	  It	  has	  been	  debated	  to	  what	  extent	  these	  loci	  explain	  the	  heritability	  of	  
human	  height,	  but	  many	  factors	  contributing	  to	  normal	  variation	  of	  human	  
height	  still	  remain	  unknown.	  	  
	  
Short	  stature,	  or	  poor	  growth	  in	  children,	  is	  a	  symptom	  that	  can	  be	  due	  to	  many	  
factors	  including	  malnutrition,	  systemic	  disorders,	  or	  an	  underlying	  genetic	  or	  
epigenetic	  defect.	  Genomic	  studies	  have	  located	  many	  monogenic	  disorders	  
responsible	  for	  severe	  short	  stature.	  Finding	  the	  molecular	  cause	  for	  a	  growth	  
disorder	  is	  important	  for	  planning	  appropriate	  care	  and	  genetic	  counseling.	  	  
	  
SRS	  is	  a	  rare	  human	  growth	  disorder,	  in	  which	  both	  prenatal	  and	  postnatal	  
growth	  is	  affected.	  SRS	  patients	  are	  born	  small	  for	  gestational	  age,	  they	  are	  
shorter	  than	  their	  peers	  during	  childhood	  and	  reach	  an	  adult	  height	  below	  that	  
of	  the	  usual	  height	  variation.	  SRS	  belongs	  to	  a	  group	  of	  disorders	  called	  
imprinting	  disorders,	  which	  often	  affect	  growth	  and	  neurological	  functioning.	  
While	  most	  human	  genes	  are	  expressed	  from	  both	  parents,	  imprinted	  genes	  are	  
an	  exception	  to	  the	  rule	  –	  they	  are	  expressed	  solely	  or	  predominantly	  either	  from	  	  
a	  person’s	  mother	  or	  father,	  not	  both.	  DNA	  methylation,	  the	  addition	  of	  methyl	  
groups	  to	  DNA,	  is	  the	  most	  important	  and	  easily	  assayed	  epigenetic	  mark	  
involved	  in	  imprinting.	  In	  SRS,	  imprinted	  genes	  can	  be	  dysregulated	  either	  
through	  genomic	  aberrations	  or	  epimutations,	  but	  for	  a	  large	  part	  of	  SRS	  patients	  
the	  etiology	  remains	  unknown.	  	  
	  
The	  studies	  in	  this	  thesis	  utilize	  multiple	  approaches,	  such	  as	  genome-­‐wide	  
arrays	  and	  targeted	  studies,	  to	  explore	  the	  genetic	  and	  epigenetic	  factors	  
contributing	  to	  SRS.	  Those	  factors	  are	  then	  examined	  in	  other	  growth-­‐restricted	  
children	  without	  SRS,	  as	  well	  as	  in	  children	  of	  normal	  growth.	  Additionally,	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epigenetic	  changes	  are	  studied	  in	  adults	  born	  pre-­‐term	  at	  very	  low	  birth	  weight,	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REVIEW	  OF	  THE	  LITERATURE	  	  
The	  human	  genome	  
All	  human	  cells	  contain	  hereditary	  information	  in	  the	  form	  of	  deoxyribonucleic	  
acid	  (DNA).	  Most	  DNA	  is	  located	  in	  the	  cell	  nucleus,	  while	  a	  small	  part	  is	  present	  
in	  mitochondria.	  DNA	  consists	  of	  nucleotides,	  units	  containing	  a	  deoxyribose	  
sugar,	  a	  phosphate	  group	  and	  one	  of	  four	  bases:	  adenine	  (A),	  thymine	  (T),	  
guanine	  (G)	  and	  cytosine	  (C).	  DNA	  has	  a	  double-­‐helix	  structure,	  in	  which	  the	  
bases	  on	  opposite	  strands	  are	  connected	  by	  hydrogen	  bonds:	  A	  bonds	  with	  T,	  
and	  C	  bonds	  with	  G.	  	  
	  
Nuclear	  DNA	  is	  packaged	  in	  bead-­‐like	  units	  called	  nucleosomes,	  which	  consist	  of	  
two	  turns	  of	  genomic	  DNA	  wrapped	  around	  eight	  histones	  (two	  of	  each	  of	  the	  
four	  types:	  H2A,	  H2B,	  H3	  and	  H4).	  These	  nucleosomes	  make	  up	  chromatin	  that	  
exists	  in	  two	  different	  forms:	  a	  loose	  decondensed	  form	  called	  euchromatin	  that	  
allows	  for	  DNA	  regulatory	  processes	  to	  take	  place,	  and	  a	  condensed	  
heterochromatin	  that	  generally	  lacks	  regulatory	  activity	  (Tollefsbol,	  2011).	  
Further	  folding	  and	  condensing	  of	  the	  chromatin	  during	  cell	  division	  makes	  a	  
chromosome	  visible	  under	  a	  microscope.	  	  	  
	  
Most	  human	  cells	  contain	  22	  pairs	  of	  autosomal	  chromosomes	  and	  one	  pair	  of	  
sex	  chromosomes,	  XX	  for	  females	  and	  XY	  for	  males.	  One	  chromosome	  of	  each	  
pair	  is	  inherited	  from	  the	  mother	  and	  one	  from	  the	  father.	  Altogether	  these	  
chromosomes	  contain	  around	  3	  billion	  DNA	  base	  pairs	  and	  more	  than	  20	  000	  
protein-­‐coding	  genes	  (Willyard,	  2018).	  Mitochondrial	  DNA	  exists	  in	  circular	  
molecules	  of	  16	  569	  DNA	  base	  pairs	  that	  encode	  for	  37	  genes	  (Shokolenko	  &	  














Figure	  1.	  Packaging	  of	  DNA.	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The	  central	  dogma	  of	  molecular	  biology	  describes	  how	  genetic	  information	  from	  
DNA	  is	  transcribed	  into	  ribonucleic	  acid	  (RNA),	  which	  is	  then	  translated	  into	  
protein.	  Protein-­‐coding	  genes	  contain	  exons,	  which	  are	  the	  protein-­‐coding	  
segments,	  and	  introns,	  which	  do	  not	  code	  for	  a	  protein.	  During	  transcription,	  
both	  exons	  and	  introns	  are	  first	  transcribed	  to	  messenger	  RNA	  (mRNA).	  Introns	  
are	  then	  removed	  by	  splicing	  and	  the	  final	  mRNA	  is	  translated	  into	  protein.	  Gene	  
transcription	  is	  activated	  and	  regulated	  by	  transcription	  factors	  that	  bind	  to	  
specific	  DNA	  sequences	  (transcription	  factor	  binding	  sites,	  TFBS)	  at	  gene	  
promoters	  or	  enhancers	  (Lenhard	  et	  al.,	  2012).	  The	  accessibility	  of	  regulatory	  
elements	  to	  transcription	  factors	  is	  affected	  by	  chromatin	  structures	  and	  
transcription	  factors	  can	  gain	  access	  to	  regulatory	  elements	  by	  recruitment	  of	  
chromatin-­‐modifying	  activities	  (Voss	  &	  Hager,	  2014).	  Many	  promoters	  colocalize	  
with	  CpG	  islands,	  which	  are	  regions	  rich	  in	  CpG	  dinucleotides.	  Transcription	  
factor	  binding	  can	  also	  be	  strongly	  influenced	  by	  DNA	  methylation	  (the	  addition	  
of	  a	  methyl	  group	  to	  the	  cytosine	  of	  a	  CpG	  dinucleotide)	  at	  transcription	  factor	  
binding	  sites	  (Jones,	  2012).	  	  
	  
Variation	  in	  the	  human	  genome	  
Variation	  in	  the	  human	  genome	  contributes	  to	  the	  differences	  between	  the	  
phenotypes	  of	  individuals	  and	  can	  sometimes	  lead	  to	  disease.	  This	  variation	  
ranges	  from	  changes	  of	  a	  single	  nucleotide	  to	  large	  changes	  involving	  parts	  of	  
chromosomes	  or	  even	  entire	  chromosomes.	  Mutations	  of	  single	  nucleotides	  can	  
occur	  by	  substitution,	  deletion	  or	  insertion	  of	  a	  nucleotide	  (Figure	  2).	  Single	  
nucleotide	  polymorphisms	  (SNPs)	  are	  a	  type	  of	  variation	  of	  a	  single	  nucleotide,	  
occurring	  in	  the	  normal	  population	  with	  a	  frequency	  >1%.	  Larger	  mutations	  
include	  copy	  number	  variations	  (CNVs),	  such	  as	  deletions	  and	  duplications,	  that	  
result	  in	  gain	  or	  loss	  of	  genetic	  information	  (Figure	  2).	  Copy	  number	  neutral	  
variations	  of	  the	  genome	  include	  inversions,	  translocations	  and	  uniparental	  
disomy	  (UPD).	  	  




Figure	  2.	  Mutations	  of	  variable	  sizes.	  Modified	  from	  www.genome.gov	  (National	  
Human	  Genome	  Research	  Institute)	  
Epigenetics	  
The	  term	  epigenetics	  can	  be	  defined	  as	  "the	  collective	  heritable	  changes	  in	  
phenotype	  due	  to	  processes	  that	  arise	  independent	  of	  primary	  DNA	  sequence”	  
(Tollefsbol,	  2011).	  The	  term	  ”epi-­‐”	  also	  means	  ”on	  top	  of”,	  which	  refers	  to	  
changes	  that	  are	  additional	  to	  the	  DNA	  sequence.	  Epigenetic	  mechanisms,	  such	  
as	  DNA	  methylation	  and	  histone	  modifications,	  cause	  changes	  in	  gene	  expression	  
without	  altering	  the	  genome.	  DNA	  methylation	  refers	  to	  the	  addition	  of	  a	  methyl	  
(CH3)	  group	  to	  the	  5-­‐position	  of	  the	  cytosine	  of	  a	  CpG	  dinucleotide	  by	  
methyltransferase	  enzymes	  (DNMTs).	  DNA	  methylation	  is	  heritable	  in	  cell	  
division	  and	  it	  often	  results	  in	  down-­‐regulation	  of	  gene	  activity	  when	  present	  in	  
a	  gene	  regulatory	  region.	  Chromatin	  structure	  is	  influenced	  by	  post-­‐translational	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modifications	  to	  the	  histone	  proteins,	  such	  as	  acetylation	  or	  methylation.	  
Increased	  histone	  acetylation	  is	  generally	  associated	  with	  increased	  gene	  
activity,	  whereas	  histone	  methylation	  can	  be	  activating	  or	  repressing	  depending	  
on	  the	  type	  of	  modification.	  Histone	  modifications	  also	  often	  coordinate	  with	  










Figure	  3.	  DNA	  methylation	  
	  
Epigenetics	  plays	  a	  role	  in	  a	  number	  of	  important	  processes,	  such	  as	  cellular	  
differentiation,	  X	  chromosome	  inactivation	  and	  genomic	  imprinting.	  This	  thesis	  
is	  largely	  focused	  on	  genomic	  imprinting	  and	  DNA	  methylation	  changes.	  	  
Genomic	  imprinting	  
Imprinted	  genes	  are	  a	  small	  group	  of	  genes	  that	  are	  solely	  or	  predominantly	  
expressed	  from	  one	  parental	  chromosome.	  Through	  epigenetic	  mechanisms,	  one	  
parental	  allele	  is	  silenced,	  while	  the	  other	  is	  expressed.	  This	  parent-­‐of-­‐origin	  
dependent	  expression	  is	  essential	  for	  normal	  development.	  A	  disturbance	  that	  
alters	  the	  normal	  dosage	  of	  imprinted	  genes	  can	  lead	  to	  abnormalities	  in	  growth	  
and	  neurological	  functioning	  (Ishida	  &	  Moore,	  2013).	  Loss	  of	  imprinting	  is	  also	  
linked	  to	  the	  development	  of	  cancer	  (Feinberg	  et	  al.,	  2006).	  
	  
Genomic	  imprinting	  was	  first	  discovered	  by	  studies	  that	  produced	  mouse	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Solter,	  1984)	  (Surani	  et	  al.,	  1984)	  (Barton	  et	  al.,	  1984).	  It	  was	  observed	  that	  the	  
androgenetic	  or	  gynogenetic	  embryos	  did	  not	  complete	  normal	  embryogenesis	  
(McGrath	  &	  Solter,	  1984).	  The	  male-­‐derived	  embryos	  developed	  poorly	  with	  
relatively	  well-­‐developed	  extraembryonic	  tissues,	  while	  the	  female-­‐derived	  
embryos	  had	  a	  better	  embryonic	  development	  with	  poor	  extraembryonic	  tissues	  
(Barton	  et	  al.,	  1984)(Surani	  et	  al,	  1984).	  These	  studies	  demonstrated	  that	  
maternal	  and	  paternal	  genomes	  are	  not	  equal	  and	  that	  contribution	  from	  both	  
parents	  is	  required	  for	  normal	  embryogenesis.	  	  
Studies	  of	  mice	  with	  uniparental	  disomies	  demonstrated	  that	  certain	  
chromosomes,	  such	  as	  chromosome	  11,	  contain	  imprinted	  regions.	  Mice	  with	  
two	  maternal	  copies	  of	  chromosome	  11	  were	  consistently	  smaller,	  and	  mice	  with	  
two	  paternal	  copies	  were	  consistently	  larger	  than	  their	  littermates	  (Cattanach	  &	  
Kirk,	  1985).	  Observations	  of	  the	  inequality	  of	  parental	  genomes	  lead	  to	  the	  
parental	  conflict	  (kinship)	  theory,	  which	  proposed	  that	  imprinting	  evolved	  in	  
mammals	  because	  of	  conflict	  of	  interest	  between	  the	  maternal	  and	  paternal	  
genomes	  in	  relation	  to	  the	  transfer	  of	  nutrients	  from	  the	  mother	  to	  the	  offspring	  
(Moore	  &	  Haig,	  1991).	  According	  to	  the	  theory,	  paternally	  expressed	  imprinted	  
genes	  would	  act	  to	  extract	  resources	  from	  the	  mother	  to	  achieve	  maximal	  fetal	  
growth	  for	  the	  offspring,	  while	  maternally	  expressed	  imprinted	  genes	  would	  act	  
in	  the	  opposite	  way	  to	  conserve	  maternal	  resources	  in	  order	  to	  enable	  possible	  
future	  pregnancies.	  	  
Single	  imprinted	  genes	  were	  first	  identified	  in	  1991	  in	  mouse	  studies,	  when	  
insulin-­‐like	  growth	  factor	  2	  receptor	  (Igf2r)	  (Barlow	  et	  al.,	  1991),	  Igf2	  (DeChiara	  
et	  al.,	  1991)	  and	  H19,	  imprinted	  maternally	  expressed	  transcript	  (H19)	  
(Bartolomei	  et	  al.,	  1991),	  were	  described	  as	  imprinted.	  Currently	  there	  are	  a	  100	  
known	  imprinted	  genes	  in	  human,	  more	  than	  a	  100	  predicted	  imprinted	  genes	  
and	  additional	  genes	  with	  provisional	  or	  conflicting	  data	  about	  imprinting	  (Jirtle,	  
Imprinted	  Gene	  Databases).	  	  
Imprinting	  involves	  various	  mechanisms,	  including	  DNA	  methylation,	  histone	  
modifications,	  chromatin	  insulators	  and	  non-­‐coding	  RNAs	  (Lewis	  &	  Reik,	  2006).	  
Most	  imprinted	  genes	  are	  located	  in	  clusters	  that	  are	  regulated	  by	  chromatin	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insulators	  or	  long	  non-­‐coding	  RNAs	  (lncRNAs)	  (Barlow	  &	  Bartolomei,	  2014).	  
DNA	  methylation	  has	  a	  central	  role	  in	  imprinting	  because	  the	  maternal	  and	  
paternal	  alleles	  can	  be	  distinguished	  from	  one	  another	  when	  only	  one	  parental	  
allele	  is	  methylated	  at	  differentially	  methylated	  regions	  (DMRs).	  Some	  DMRs	  
function	  as	  imprinting	  centers	  (ICs),	  known	  also	  as	  imprinting	  control	  regions	  
(ICRs)	  (Lewis	  &	  Reik,	  2006).	  ICRs	  control	  the	  expression	  of	  the	  genes	  in	  the	  
imprinting	  cluster	  in	  a	  parent-­‐of-­‐origin	  specific	  manner.	  	  
	  
Parental	  imprints	  are	  reprogrammed	  at	  each	  generation	  to	  allow	  establishment	  
of	  the	  imprints	  according	  to	  the	  sex	  of	  the	  contributing	  parent	  for	  the	  next	  
generation.	  During	  reproduction,	  global	  epigenetic	  reprogramming	  occurs	  first	  
in	  the	  germline	  and	  again	  at	  fertilization	  (reviewed	  in	  Mackay	  &	  Temple,	  2017).	  
The	  first	  wave	  of	  reprogramming	  affects	  also	  imprinted	  genes,	  so	  that	  imprints	  
are	  erased	  in	  the	  germline	  and	  then	  re-­‐set	  according	  to	  the	  parental	  origin.	  The	  
parental	  imprints,	  however,	  are	  not	  affected	  by	  the	  second	  wave	  of	  
reprogramming	  after	  fertilization.	  These	  imprints	  are	  mitotically	  stable	  and	  they	  
are	  maintained	  throughout	  development	  of	  the	  organism	  (Horsthemke,	  2010).	  
DNA	  methyltransferases,	  including	  DNA	  methyltransferase	  3A	  (DNMT3A)	  and	  
DNA	  methyltransferase	  3B	  (DNMT3B),	  are	  essential	  for	  establishment	  of	  the	  
DNA	  methylation	  patterns	  in	  early	  development	  (Jones,	  2012).	  DNA	  
methyltransferase	  1	  (DNMT1),	  together	  with	  DNMT3A	  and	  DNMT3B,	  is	  required	  
for	  methylation	  maintenance	  (Jones	  &	  Liang,	  2009).	  
	  
Although,	  in	  general,	  imprinted	  genes	  are	  expressed	  from	  one	  parental	  allele	  and	  
not	  the	  other,	  the	  silenced	  allele	  is	  not	  always	  completely	  silenced	  but	  may	  have	  
residual	  activity	  (Horsthemke,	  2010).	  Imprinting	  can	  also	  be	  tissue-­‐	  and	  
developmental	  stage	  –specific.	  The	  expression	  of	  the	  imprinted	  gene	  ubiquitin	  
protein	  ligase	  E3A	  (Ube3a),	  for	  example,	  is	  suppressed	  to	  varying	  degrees	  in	  
different	  tissues	  (Gustin	  et	  al.,	  2010).	  It	  has	  been	  shown	  that	  the	  imprinted	  
expression	  that	  is	  present	  during	  early	  development	  may	  be	  either	  kept	  or	  lost	  in	  
adulthood	  (Babak	  et	  al.,	  2015).	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Models	  of	  imprinting	  
Insulator	  model	  
	  
CTCF-­‐binding	  sites	  can	  be	  found	  at	  imprinting	  clusters,	  where	  they	  act	  as	  
insulators	  between	  gene	  promoters	  and	  enhancers	  (Bartolomei	  &	  Ferguson-­‐
Smith,	  2011).	  One	  example	  of	  this	  type	  of	  regulation	  is	  seen	  at	  the	  Igf2-­‐H19	  
region.	  The	  ICR	  on	  the	  maternal	  allele	  is	  unmethylated	  and	  therefore	  allows	  
binding	  of	  CTCF.	  The	  bound	  CTCF	  acts	  as	  an	  insulator,	  preventing	  enhancers	  
from	  accessing	  the	  Igf2	  promoter.	  The	  enhancers	  can	  only	  access	  H19	  and	  
therefore	  H19	  is	  expressed	  from	  the	  maternal	  allele.	  Conversely,	  the	  ICR	  on	  the	  
paternal	  allele	  is	  methylated,	  preventing	  CTCF	  from	  binding	  and	  the	  insulator	  is	  
not	  formed.	  As	  a	  result,	  Igf2	  is	  activated	  by	  enhancers	  while	  H19	  is	  repressed	  on	  
the	  paternal	  chromosome	  (reviewed	  in	  Plasschaert	  &	  Bartolomei,	  2014).	  
ncRNA	  model	  
Long	  non-­‐coding	  RNAs	  (lncRNAs)	  are	  found	  in	  many	  imprinted	  gene	  clusters	  and	  
have	  been	  found	  to	  regulate	  expression	  of	  nearby	  genes	  in	  the	  clusters	  (Koerner	  
et	  al.,	  2009).	  One	  example	  is	  the	  Kcnq1	  (potassium	  voltage-­‐gated	  channel,	  
subfamily	  Q,	  member	  1)	  locus,	  where	  the	  promoter	  of	  a	  lncRNA	  Kcnq1ot1	  (Kcnq1	  
overlapping	  transcript	  1)	  is	  located	  within	  the	  ICR	  of	  the	  imprinting	  cluster.	  The	  
ICR	  on	  the	  maternal	  allele	  is	  methylated,	  which	  represses	  the	  lncRNA	  and	  the	  
nearby	  genes	  are	  thus	  activated	  on	  the	  maternal	  chromosome.	  Conversely,	  the	  
ICR	  on	  the	  paternal	  allele	  is	  unmethylated,	  allowing	  expression	  of	  the	  lncRNA,	  
which	  in	  turn	  silences	  the	  nearby	  genes.	  It	  is	  not	  fully	  understood	  how	  the	  
nearby	  genes	  are	  silenced,	  but	  it	  may	  involve	  repressive	  chromatin	  marks	  or	  
preventing	  RNA	  polymerase	  II	  recruitment	  at	  promoters	  (Plasschaert	  &	  
Bartolomei,	  2014).	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Loss	  of	  imprinting	  	  
Loss	  of	  imprinting	  (LOI)	  in	  humans	  can	  lead	  to	  imprinting	  disorders	  and	  cancer.	  	  
LOI	  at	  IGF2	  occurs	  in	  a	  range	  of	  different	  tumor	  types,	  including	  colon,	  liver,	  lung,	  
ovarian	  cancer	  and	  Wilms’	  tumor	  (Robertson,	  2005).	  In	  1994,	  Steenman	  and	  
colleagues	  described	  how	  in	  Wilms’	  tumors	  with	  LOI,	  the	  maternal	  chromosome	  
reverses	  to	  a	  paternal	  methylation	  pattern	  at	  the	  H19-­‐IGF2	  region,	  causing	  
increased	  levels	  of	  IGF2,	  decreased	  levels	  of	  H19	  and	  increased	  cell	  growth	  
(Steenman	  et	  al.,	  1994).	  Imprinting	  control	  regions	  of	  paternally	  expressed	  3	  
(PEG3),	  mesoderm	  specific	  transcript	  (MEST)	  and	  guanine	  nucleotide	  binding	  
protein	  alpha	  stimulating	  complex	  locus	  (GNAS)	  are	  affected	  in	  breast,	  lung	  and	  
ovarian	  cancers	  (Kim	  et	  al.,	  2015).	  
	  
Imprinting	  disorders	  in	  humans	  often	  cause	  phenotypes	  with	  disturbed	  growth	  
and	  neurological	  abnormalities	  (Walter	  &	  Paulsen,	  2003).	  Heterogeneous	  and	  
overlapping	  clinical	  features,	  heterogeneous	  molecular	  etiology	  including	  
mosaicism,	  as	  well	  as	  multi-­‐locus	  imprinting	  defects	  are	  also	  common	  features	  of	  
imprinting	  disorders	  (Mackay	  &	  Temple,	  2017).	  Imprinting	  disorders	  include	  
Silver-­‐Russell	  syndrome	  (SRS),	  Beckwith-­‐Wiedemann	  syndrome	  (BWS),	  
Angelman	  syndrome	  (AS),	  Prader-­‐Willi	  syndrome	  (PWS),	  Temple	  syndrome	  
(TS),	  Kagami-­‐Ogata	  syndrome	  (KOS),	  transient	  neonatal	  diabetes	  mellitus	  
(TNDM),	  pseudohypoparathyroidism	  type	  1b	  (PHP1B)	  and	  Mulchandani-­‐Bhoj-­‐
Conlin	  syndrome	  (MBCS)	  (Mackay	  &	  Temple,	  2017).	  Opposite	  changes	  in	  an	  
imprinted	  region	  can	  lead	  to	  imprinting	  disorder	  with	  contrasting	  phenotypes,	  
such	  as	  growth	  restriction	  in	  SRS	  with	  hypomethylation	  of	  H19-­‐IGF2	  intergenic	  
DMR	  (H19/IGF2:IG-­‐DMR)	  and	  overgrowth	  in	  BWS	  with	  hypermetylation	  of	  
H19/IGF2:IG-­‐DMR	  (Eggermann	  et	  al.,	  2016).	  Similarly,	  a	  paternal	  deletion	  of	  
15q11-­‐q13	  is	  seen	  in	  PWS,	  while	  a	  maternal	  deletion	  of	  the	  same	  region	  leads	  to	  
AS	  (Buiting,	  2010).	  
	  
Genomic	  aberrations	  that	  cause	  imprinting	  disorders	  include	  UPD,	  chromosomal	  
imbalances	  and	  point	  mutations.	  Imprinting	  disorders	  are	  also	  caused	  by	  
epimutations,	  which	  are	  DNA	  methylation	  defects	  without	  genomic	  alterations.	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These	  methylation	  changes	  can	  result	  from	  a	  defect	  in	  imprint	  erasure	  in	  
primordial	  germ	  cells,	  defects	  in	  imprint	  establishment	  in	  sperm	  and	  oocytes,	  or	  
defects	  in	  imprint	  maintenance	  in	  the	  embryo	  (Horsthemke,	  2010).	  	  
Causes	  of	  human	  imprinting	  disorders	  
Uniparental	  disomy	  (UPD)	  
UPD	  is	  the	  abnormal	  inheritance	  of	  both	  copies	  of	  a	  chromosome	  from	  only	  one	  
parent,	  as	  first	  described	  by	  Engel	  in	  1980	  (Engel,	  1980).	  As	  imprinted	  genes	  are	  
differentially	  expressed	  based	  on	  the	  parent-­‐of-­‐origin,	  receiving	  both	  copies	  of	  a	  
chromosome	  from	  only	  one	  parent	  results	  in	  disrupted	  expression	  pattern	  of	  
imprinted	  genes	  within	  the	  UPD	  region.	  	  
	  
Figure	  4.	  UPD	  affects	  the	  dosage	  of	  imprinted	  genes.	  Modified	  from	  Hitchins	  &	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UPD	  can	  include	  a	  whole	  chromosome	  or	  just	  a	  part	  of	  a	  chromosome,	  in	  which	  
case	  it	  is	  called	  segmental	  UPD	  (Kotzot,	  2001).	  UPD	  can	  be	  either	  heterodisomic	  
or	  isodisomic.	  In	  heterodisomy,	  both	  homologous	  chromosomes	  are	  transmitted	  
from	  the	  same	  parent,	  while	  isodisomy	  is	  the	  result	  of	  two	  copies	  of	  one	  parental	  
chromosome	  (Mergenthaler	  et	  al.,	  2000).	  Uniparental	  isodisomy	  can	  also	  cause	  
recessive	  allele	  penetrance,	  so	  that	  a	  recessive	  disease	  will	  manifest	  in	  a	  person	  
whose	  only	  one	  parent	  is	  a	  carrier	  of	  the	  disease	  allele	  (Spence	  et	  al.,	  1988).	  	  	  	  
	  
Different	  types	  of	  events	  can	  lead	  to	  UPD.	  UPD	  of	  a	  whole	  chromosome	  can	  be	  
the	  result	  of	  a	  trisomy	  or	  monosomy	  rescue,	  gamete	  complementation	  or	  post-­‐
fertilization	  error	  (Kotzot,	  2008a).	  When	  one	  parental	  gamete	  is	  disomic	  and	  the	  
other	  monosomic,	  this	  situation	  will	  lead	  to	  trisomy.	  However,	  if	  the	  extra	  
chromosome	  from	  a	  trisomic	  zygote	  is	  expelled,	  this	  is	  called	  trisomy	  rescue	  and	  
it	  will	  result	  in	  either	  a	  normal	  biparental	  zygote	  or	  lead	  to	  UPD	  if	  the	  two	  
chromosomes	  left	  in	  the	  zygote	  came	  from	  the	  same	  parent.	  In	  monosomy	  
rescue,	  monosomic	  and	  nullisomic	  gametes	  will	  combine,	  creating	  a	  monosomic	  
zygote.	  As	  a	  result	  of	  mitotic	  duplication,	  UPD	  will	  form.	  Gamete	  
complementation,	  the	  situation	  where	  disomic	  and	  nullisomic	  gametes	  combine,	  
will	  also	  lead	  to	  UPD.	  In	  postfertilization	  errors	  two	  normal	  monosomic	  gametes	  
combine,	  resulting	  in	  a	  normal	  biparental	  zygote,	  but	  a	  mitotic	  segregation	  error	  
will	  lead	  to	  trisomy	  or	  monosomy,	  after	  which	  either	  a	  loss	  or	  duplication	  of	  a	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Figure	  5.	  Causes	  of	  UPD.	  Modified	  from	  Tollefsbol,	  2011.	  
	  
Deletions	  and	  duplications	  
Chromosomal	  deletions	  and	  duplications	  are	  common	  in	  some	  imprinting	  
disorders	  and	  rare	  in	  others.	  In	  AS	  and	  PWS,	  chromosomal	  imbalances	  affect	  the	  
majority	  of	  the	  patients.	  70%	  of	  AS	  patients	  have	  a	  deletion	  on	  the	  maternal	  
chromosome	  15	  (15q11.2),	  while	  a	  paternal	  deletion	  of	  the	  same	  region	  of	  
chromosome	  15	  is	  responsible	  for	  70%	  of	  PWS	  cases.	  In	  TNDM,	  40%	  of	  the	  
patients	  have	  a	  paternal	  duplication	  on	  chromosome	  6	  (6q24).	  Maternal	  and	  
paternal	  deletions	  of	  14q32	  affect	  15	  and	  10%	  of	  KOS	  and	  TS,	  respectively.	  
Chromosomal	  aberrations	  are	  rare	  in	  SRS,	  representing	  less	  than	  1%	  of	  the	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Point	  mutations	  
Genomic	  point	  mutations	  are	  responsible	  for	  some	  cases	  of	  imprinting	  disorders.	  
These	  mutations	  may	  affect	  regulation	  of	  ICRs	  or	  genes	  involved	  in	  
establishment	  or	  maintenance	  of	  DNA	  methylation	  (Tollefsbol,	  2011).	  In	  BWS,	  
cyclin	  dependent	  kinase	  inhibitor	  1C	  (CDKN1C)	  mutations	  occur	  in	  8%	  of	  the	  
patients,	  including	  familial	  and	  sporadic	  cases	  (Brioude,	  2015).	  Approximately	  
5%	  of	  TNDM	  patients	  have	  recessive	  mutations	  of	  zinc-­‐finger	  protein	  57,	  ZFP57,	  
that	  result	  in	  loss	  of	  methylation	  at	  the	  TNDM	  locus	  and	  other	  imprinted	  loci	  
(Boonen	  et	  al.,	  2013).	  The	  mouse	  Zfp57	  has	  a	  role	  in	  both	  methylation	  
establishment	  and	  maintenance	  during	  development	  (Boonen	  et	  al.,	  2013).	  	  
Epimutations	  -­‐	  abnormal	  DNA	  methylation	  without	  genomic	  alterations	  
In	  some	  imprinting	  disorders	  such	  as	  SRS	  and	  BWS,	  the	  majority	  of	  cases	  are	  
caused	  by	  altered	  methylation	  patterns	  at	  ICRs.	  The	  11p15	  region,	  implicated	  in	  
both	  SRS	  and	  BWS,	  can	  be	  divided	  into	  two	  domains.	  The	  telomeric	  domain	  
contains	  the	  paternally	  expressed	  IGF2	  and	  maternally	  expressed	  H19,	  and	  its	  
imprinting	  is	  controlled	  by	  H19/IGF2:IG-­‐DMR	  (also	  known	  as	  ICR1,	  IC1,	  H19	  
DMR).	  Loss	  of	  methylation	  at	  the	  H19/IGF2:IG-­‐DMR	  is	  the	  most	  common	  
molecular	  cause	  of	  SRS	  and	  results	  in	  reduced	  IGF2	  expression	  and	  increased	  
H19	  expression	  (Wakeling	  et	  al.,	  2017).	  The	  opposite	  change	  in	  the	  H19/IGF2	  IG-­‐
DMR,	  gain	  of	  methylation,	  is	  the	  molecular	  cause	  of	  BWS	  in	  5-­‐10%	  of	  the	  patients	  
(Eggermann	  et	  al.,	  2014a).	  The	  centromeric	  domain	  contains	  CDKN1C	  and	  a	  
lncRNA	  KCNQ1OT1,	  controlled	  by	  the	  KCNQ1OT	  transcription	  start	  site	  DMR	  
(KCNQ1OT1:TSS-­‐DMR,	  also	  known	  as	  ICR2).	  Loss	  of	  methylation	  at	  the	  
KCNQ1OT1:TSS-­‐DMR	  accounts	  for	  BWS	  in	  50-­‐60%	  of	  patients	  (Eggermann	  et	  al.,	  
2014a).	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Silver-­‐Russell	  Syndrome	  (SRS)	  
Silver-­‐Russell	  syndrome	  is	  an	  imprinting	  disorder	  characterized	  by	  pre-­‐	  and	  
postnatal	  growth	  restriction	  and	  variable	  clinical	  features.	  SRS	  was	  first	  
discovered	  independently	  by	  Silver	  and	  colleagues	  (Silver	  et	  al.,	  1953),	  and	  
Russell	  (Russell,	  1954),	  who	  described	  children	  with	  growth	  restriction	  and	  
additional	  clinical	  characteristics,	  such	  as	  body	  asymmetry	  and	  specific	  facial	  
features.	  In	  addition	  to	  poor	  prenatal	  and	  postnatal	  growth,	  the	  main	  additional	  
features	  in	  SRS	  include	  relative	  macrocephaly,	  protruding	  forehead,	  body	  
asymmetry	  and	  feeding	  difficulties	  (Wakeling	  et	  al.,	  2017).	  SRS	  is	  very	  
heterogeneous	  in	  both	  phenotype	  and	  molecular	  etiology.	  The	  incidence	  of	  SRS	  is	  
estimated	  to	  be	  1/3000	  to	  1/100	  000	  (Abu-­‐Amero	  et	  al.,	  2008).	  In	  a	  study	  of	  386	  
SRS	  patients,	  the	  mean	  adult	  height	  was	  reported	  151	  +/-­‐	  7.8	  cm	  for	  males	  and	  
139.9	  +/-­‐	  9.0	  cm	  for	  females	  (Wollmann	  et	  al.,	  1995).	  	  
Diagnosis	  
The	  diagnosis	  of	  SRS	  can	  be	  challenging	  due	  to	  the	  heterogeneity	  of	  the	  
phenotype.	  Multiple	  clinical	  scoring	  systems	  have	  been	  developed	  and	  used	  in	  
diagnosis.	  The	  first	  international	  SRS	  consensus	  statement	  (Wakeling	  et	  al.,	  
2017),	  presents	  the	  Netchine-­‐Harbison	  clinical	  scoring	  system	  (NH-­‐CSS)(Azzi	  et	  
al.,	  2015)	  for	  investigation	  and	  diagnosis	  of	  SRS.	  It	  is	  more	  sensitive	  (98%)	  than	  
some	  of	  the	  other	  scoring	  systems	  (Wakeling	  et	  al.,	  2017).	  NH-­‐CSS	  uses	  six	  
clearly	  defined	  criteria	  (Table	  1).	  Clinical	  SRS	  diagnosis	  is	  given	  when	  at	  least	  
four	  of	  the	  criteria	  are	  fulfilled.	  However,	  in	  the	  original	  publication	  of	  the	  
scoring	  system,	  the	  NH-­‐CSS	  system	  missed	  one	  SRS	  patient	  with	  UPD(7)mat,	  who	  
only	  fulfilled	  three	  of	  the	  criteria	  (Azzi	  et	  al.,	  2015).	  Molecular	  testing	  for	  SRS	  is	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SRS	  clinical	  criteria	   Definition	  
Prenatal	  growth	  
retardation	  
Birth	  length	  and/or	  weight	  ≤-­‐2	  SDS	  for	  gestational	  age	  
Postnatal	  growth	  
retardation	  
Height	  at	  24	  ±1	  months	  ≤−2	  SDS	  or	  height	  ≤−2	  SDS	  from	  
midparental	  target	  height	  
Relative	  macrocephaly	  at	  
birth	  
Head	  circumference	  at	  birth	  at	  least	  1.5	  SDS	  above	  birth	  weight	  
and/or	  length	  SDS	  
Protruding	  forehead	   Forehead	  that	  projects	  beyond	  the	  facial	  plane	  on	  a	  side	  view	  as	  a	  
toddler	  
Body	  asymmetry	   Leg	  length	  discrepancy	  of	  at	  least	  0.5	  cm	  or	  arm	  asymmetry	  or	  leg	  
length	  discrepancy	  less	  than	  0.5	  cm	  with	  at	  least	  two	  asymmetrical	  
body	  parts	  (one	  non-­‐face)	  
Feeding	  difficulties	  and/or	  
low	  BMI	  
Use	  of	  a	  feeding	  tube	  or	  cyproheptadine	  for	  appetite	  stimulation	  
and/or	  BMI	  ≤-­‐2	  SDS	  at	  24	  months	  
	  
Table	  1.	  Clinical	  criteria	  for	  diagnosis	  of	  SRS.	  According	  to	  Wakeling	  et	  al.,	  2017	  
and	  Azzi	  et	  al.,	  2015.	  	  
	  
Additional	  clinical	  features	  of	  SRS	  	  	  
In	  addition	  to	  the	  main	  features	  listed	  in	  the	  diagnostic	  criteria,	  SRS	  patients	  
have	  many	  features	  that	  are	  present	  at	  varying	  frequencies.	  Triangular	  face	  is	  
seen	  in	  94%	  of	  SRS	  patients,	  fifth	  finger	  clinodactyly	  in	  75%,	  micrognathia	  in	  
62%,	  low	  muscle	  mass	  in	  56%,	  excessive	  sweating	  in	  54%,	  low-­‐set	  or	  posteriorly	  
rotated	  ears	  in	  49%,	  down-­‐turned	  mouth	  in	  48%,	  high-­‐pitched	  or	  squeaky	  voice	  
in	  45%,	  speech	  delay	  in	  40%,	  male	  genital	  abnormalities	  in	  40%,	  motor	  delay	  in	  
37%,	  syndactyly	  of	  toes	  in	  30%,	  among	  other	  features	  (Wakeling	  et	  al.,	  2017).	  
These	  features	  are	  not	  specific	  to	  SRS,	  but	  are	  present	  at	  a	  higher	  frequency	  SRS	  
than	  in	  non-­‐SRS	  patients.	  Global	  developmental	  delay	  or	  learning	  difficulties	  
have	  been	  described	  in	  some	  SRS	  patients,	  especially	  in	  the	  UPD(7)mat	  
subgroup.	  (Wakeling	  et	  al.,	  2017)	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Clinical	  management	  
SRS	  is	  an	  indication	  for	  growth	  hormone	  (GH)	  treatment,	  which	  increases	  the	  
adult	  height	  of	  the	  patients.	  The	  gain	  in	  height	  has	  been	  reported	  similar	  in	  SRS	  
children	  and	  non-­‐SRS	  children	  who	  are	  small	  for	  gestational	  age	  (SGA),	  with	  a	  
total	  height	  gain	  of	  1.3	  SDS	  in	  SRS	  and	  1.26	  SDS	  in	  non-­‐SRS	  SGA	  children	  (Smeets	  
et	  al.,	  2016),	  however	  noting	  that	  final	  adult	  height	  of	  SRS	  patients	  will	  be	  lower	  
than	  that	  of	  the	  non-­‐SRS	  SGA	  patients	  because	  of	  more	  severe	  growth	  restriction	  
and	  earlier	  onset	  of	  puberty.	  A	  trend	  has	  been	  reported	  towards	  UPD(7)mat	  
patients	  having	  a	  greater	  benefit	  from	  GH	  treatment	  than	  those	  with	  11p15	  
epimutation	  (Binder	  et	  al.,	  2008)(Smeets	  et	  al.,	  2016).	  	  	  
	  
SRS	  children	  often	  suffer	  from	  malnutrition,	  which	  may	  limit	  the	  benefits	  of	  GH	  
treatment	  on	  height	  (Marsaud	  et	  al.,	  2015).	  Nutritional	  management	  is	  therefore	  
essential	  and	  may	  include	  nutritional	  support,	  such	  as	  enriched	  diet,	  oral	  
nutritional	  supplements	  and	  enteral	  feeding	  (Marsaud	  et	  al.,	  2015).	  However,	  
because	  rapid	  weight	  gain	  in	  children	  born	  SGA	  is	  associated	  with	  an	  increased	  
metabolic	  and	  cardiovascular	  risk	  later	  in	  life,	  it	  is	  essential	  to	  avoid	  overfeeding	  
SRS	  children	  (Wakeling	  et	  al.,	  2017).	  
	  
Other	  clinical	  management	  strategies	  in	  SRS	  children	  include	  prevention	  of	  
hypoglycemia,	  monitoring	  for	  signs	  of	  premature	  adrenarche	  and	  insulin	  
resistance,	  assessment	  of	  neurocognitive	  problems	  including	  speech	  delay,	  and	  
management	  of	  orthopedic	  problems,	  such	  as	  asymmetry	  and	  limb	  anomalies.	  
(Wakeling	  et	  al.,	  2017).	  A	  recent	  study	  also	  suggests	  that	  SRS	  patients	  experience	  
psychosocial	  issues,	  including	  appearance-­‐related	  concerns,	  and	  could	  benefit	  
from	  early	  psychosocial	  intervention	  (Ballard	  et	  al.,	  2018).	  
Differential	  diagnosis	  
As	  features	  of	  SRS	  are	  heterogeneous	  and	  overlap	  with	  other	  growth	  disorders,	  
differential	  diagnosis	  can	  be	  challenging.	  Syndromes	  that	  are	  very	  close	  in	  
clinical	  phenotype	  are	  Mulibrey	  nanism	  (MUscle,	  LIver,	  BRain,	  EYes	  nanism)	  and	  
3-­‐M	  (Miller,	  McKusick,	  and	  Malvaux)	  syndrome.	  Mulibrey	  nanism	  and	  SRS	  
patients	  both	  have	  intrauterine	  growth	  failure,	  lack	  of	  postnatal	  catch-­‐up	  growth,	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feeding	  difficulties	  and	  similar	  facial	  dysmorphisms.	  Features	  that	  may	  help	  
distinguish	  SRS	  and	  Mulibrey	  from	  each	  other	  are	  clinodactyly,	  micrognathia,	  
down-­‐turned	  mouth	  corners	  and	  asymmetry,	  which	  are	  characteristic	  of	  SRS,	  
and	  hepatomegaly,	  heart	  failure	  (due	  to	  pericardial	  constriction	  or	  
cardiomyopathy),	  yellow	  dots	  in	  ocular	  fundi	  and	  fibrous	  dysplasia	  of	  long	  bone,	  
which	  do	  not	  occur	  in	  SRS	  patients	  (Karlberg	  et	  al.,	  2004).	  3-­‐M	  syndrome	  and	  
SRS	  patients	  both	  have	  pre-­‐	  and	  postnatal	  growth	  restriction,	  relatively	  large	  
head	  and	  triangular	  face,	  and	  in	  multiple	  cases	  patients	  initially	  diagnosed	  with	  
autosomal	  recessive	  SRS	  have	  been	  later	  found	  to	  have	  mutations	  related	  to	  3-­‐M	  
syndrome	  (Akawi	  et	  al.,	  2011).	  Other	  syndromes	  that	  have	  been	  suggested	  for	  
differential	  diagnosis	  in	  patients	  with	  normo-­‐	  or	  macrocephaly	  are	  SHORT	  (short	  
stature,	  hyperextensibility	  of	  joints,	  ocular	  depression,	  Rieger	  anomaly	  and	  
teething	  delay)	  syndrome,	  Floating	  harbour	  syndrome	  and	  IMAGe	  (intrauterine	  
growth	  restriction,	  metaphyseal	  dysplasia,	  congenital	  adrenal	  hypoplasia,	  genital	  
anomalies)	  syndrome,	  and	  for	  patients	  with	  relative	  microcephaly,	  Bloom	  
syndrome,	  Nijmegen	  breakage	  syndrome,	  Microcephalic	  osteodysplastic	  
primordial	  dwarfism	  type	  II,	  Meier-­‐Gorlin	  syndrome,	  IGF1R	  mutation	  or	  deletion	  
and	  insulin-­‐like	  growth	  factor	  (IGF1)	  mutation	  (Wakeling	  et	  al.,	  2017).	  
	  
Etiology	  of	  SRS	  
Maternal	  UPD	  of	  chromosome	  7	  [UPD(7)mat]	  
	  
Maternal	  uniparental	  disomy	  for	  chromosome	  7,	  UPD(7)mat,	  was	  the	  first	  
molecular	  diagnosis	  suggested	  in	  SRS	  by	  Kotzot	  and	  colleagues	  in	  1995,	  when	  
they	  found	  three	  cases	  of	  UPD(7)mat	  among	  35	  patients	  with	  SRS	  or	  primordial	  
growth	  restriction	  (Kotzot	  et	  al.,	  1995).	  Previously,	  UPD(7)mat	  had	  been	  
detected	  in	  two	  patients	  with	  short	  stature	  and	  cystic	  fibrosis	  (CF),	  where	  only	  
the	  mother	  was	  a	  carrier	  of	  CF	  (Spence	  et	  al.,	  1988)(Voss	  et	  al.,	  1989)	  and	  in	  one	  
patient	  with	  short	  stature	  and	  a	  homozygous	  mutation	  for	  collagen	  type	  I	  alpha	  2	  
chain	  (COL1A2),	  where	  only	  the	  mother	  was	  a	  carrier	  for	  the	  mutation	  (Spotila	  et	  
al.,	  1992).	  UPD(7)mat	  can	  therefore	  lead	  to	  short	  stature,	  as	  well	  as	  recessive	  
disease	  allele	  penetrance.	  Subsequent	  studies	  include	  findings	  of	  UPD(7)mat	  in	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6%	  (Preece	  et	  al.,	  1997),	  10%	  (Eggermann	  et	  al.,	  1997)	  and	  12.5%	  of	  SRS	  
patients	  (Hannula	  et	  al.,	  2001b).	  	  
	  
There	  are	  multiple	  imprinted	  genes	  on	  chromosome	  7,	  and	  it	  is	  thought	  that	  the	  
disrupted	  imprinting	  pattern	  resulting	  from	  two	  maternal	  copies	  of	  chromosome	  
7	  causes	  the	  SRS	  phenotype.	  Although	  UPD	  in	  SRS	  has	  been	  researched	  widely,	  it	  
is	  still	  unclear	  which	  imprinted	  genes	  in	  chromosome	  7	  cause	  SRS.	  Segmental	  
UPDs	  and	  copy	  number	  variants	  (CNVs)	  that	  have	  been	  reported	  in	  SRS	  have	  
suggested	  candidate	  gene	  regions,	  such	  as	  growth	  factor	  receptor	  bound	  protein	  
10	  (GRB10,	  at	  7p12.1)	  and	  MEST	  (at	  7q32).	  Reported	  segmental	  UPD(7)mat	  
cases	  include	  UPD(7q31-­‐qter)mat	  (Hannula	  et	  al.	  2001a),	  mosaic	  UPD(7q21-­‐
qter)mat	  in	  a	  patient	  with	  severe	  intrauterine	  and	  postnatal	  growth	  restriction	  
(Reboul	  et	  al.,	  2006),	  and	  two	  patients	  with	  UPD(7q11.2-­‐qter)mat	  with	  slight	  SRS	  
features	  (Eggermann	  et	  al.,	  2008).	  Gerbrands	  and	  colleagues	  recently	  also	  
reported	  of	  a	  SRS	  patient	  with	  cystic	  fibrosis	  and	  segmental	  maternal	  isodisomy	  
of	  chromosome	  7,	  covering	  at	  least	  7q31-­‐34	  (Gerbrands	  et	  al.,	  2017).	  	  
	  
The	  clinical	  phenotype	  of	  UPD(7)mat	  is	  milder	  than	  that	  of	  other	  SRS	  patients	  
(Hannula	  et	  al.,	  2001b).	  Binder	  and	  colleagues	  have	  reported	  that	  birth	  length	  
was	  significantly	  higher	  in	  SRS	  patients	  with	  UPD(7)mat	  than	  those	  with	  11p15	  
LOM	  (Binder	  et	  al.,	  2008).	  Bruce	  and	  colleagues	  have	  reported	  lower	  incidence	  of	  
certain	  features	  such	  as	  asymmetry,	  clinodactyly	  and	  down-­‐turned	  mouth	  
corners	  in	  UPD(7)mat	  patients	  and	  a	  greater	  incidence	  of	  speech	  delay,	  feeding	  
difficulties	  and	  a	  high-­‐pitched	  voice,	  among	  other	  findings	  (Bruce	  et	  al.,	  2009).	  
Wakeling	  and	  colleagues	  also	  reported	  less	  asymmetry,	  clinodactyly	  and	  
congenital	  anomalies	  in	  UPD(7)mat	  patients	  than	  in	  11p15	  LOM	  patients,	  while	  
learning	  difficulties	  and	  referral	  for	  speech	  therapy	  was	  more	  common	  
(Wakeling	  et	  al.,	  2010).	  UPD(7)mat	  patients	  have	  been	  reported	  with	  
significantly	  higher	  maternal	  and	  paternal	  ages	  (Bruce	  et	  al.,	  2009),	  which	  
increase	  the	  risk	  for	  uniparental	  disomy	  (Robinson	  et	  al.,	  1993).	  
	  
Interestingly,	  while	  UPD(7)mat	  results	  in	  a	  clear	  growth	  restriction	  phenotype,	  
in	  UPD(7)pat	  cases	  no	  growth	  abnormalities	  have	  been	  reported	  (Höglund	  et	  al.,	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1994)(Pan	  et	  al.,	  1998)(Le	  Caignec	  et	  al.,	  2007).	  	  
	  
Loss	  of	  methylation	  at	  11p15	  (11p15	  LOM)	  
	  
Gicquel	  and	  colleagues	  were	  the	  first	  to	  report	  loss	  of	  methylation	  at	  the	  
H19/IGF2:IG-­‐DMR	  in	  five	  out	  of	  nine	  SRS	  patients	  (Gicquel	  et	  al.,	  2005),	  but	  the	  
same	  region	  had	  been	  previously	  found	  to	  be	  associated	  with	  maternal	  
duplications	  in	  patients	  with	  growth	  restriction	  (Fisher	  et	  al.,	  2002)	  and	  SRS	  
(Eggermann	  et	  al.,	  2005).	  Later	  studies	  found	  11p15	  LOM	  in	  approximately	  20-­‐
60%	  of	  SRS	  patients	  (Eggermann	  et	  al.,	  2006)(Bliek	  et	  al.,	  2006)(Schönherr	  et	  al.,	  
2006).	  	  
	  
11p15	  LOM	  is	  associated	  with	  a	  more	  severe	  or	  classic	  SRS	  phenotype	  than	  other	  
SRS	  patients.	  Asymmetry	  is	  more	  common	  in	  11p15	  LOM	  than	  in	  other	  SRS	  
patients	  (Netchine	  et	  al.,	  2007)(Binder	  et	  al.,	  2008)(Bruce	  et	  al.,	  2009)(Bartholdi	  
et	  al.,	  2009)(Wakeling	  et	  al.,	  2010).	  Birth	  weight,	  birth	  length	  and	  postnatal	  body	  
mass	  index	  (BMI)	  were	  significantly	  lower,	  and	  a	  prominent	  forehead	  and	  
relative	  macrocephaly	  were	  significantly	  more	  frequent	  in	  SRS	  patients	  with	  
11p15	  LOM	  than	  in	  patients	  without	  11p15	  LOM	  (Netchine	  et	  al.,	  2007).	  Also	  
Binder	  and	  colleagues	  reported	  typical	  facial	  features	  more	  frequent	  in	  11p15	  
LOM	  SRS	  than	  other	  SRS	  patients	  (Binder	  et	  al.,	  2008).	  Fifth	  finger	  clino-­‐	  and	  
brachydactyly,	  cryptorchidism,	  syndactyly	  of	  toes,	  and	  down-­‐turned	  mouth	  
corners	  were	  more	  common	  in	  11p15	  LOM	  patients	  compared	  to	  UPD(7)mat	  
(Bruce	  et	  al.,	  2009).	  Also	  Wakeling	  and	  colleagues	  reported	  fifth	  finger	  
clinodactyly	  and	  congenital	  anomalies	  as	  more	  common	  in	  patients	  with	  11p15	  
LOM	  than	  in	  patients	  with	  UPD(7)mat	  (Wakeling	  et	  al.,	  2010).	  Patients	  with	  
extreme	  11p15	  LOM	  were	  reported	  to	  have	  abnormally	  high	  lumbar	  vertebrae,	  
lumbar	  hypomobility,	  elbow	  subluxations	  and	  specific	  hand	  and	  foot	  anomalies	  
(Bruce	  et	  al.,	  2009).	  	  
	  
Gicquel	  and	  colleagues	  found	  low	  expression	  of	  IGF2	  in	  skin	  fibroblasts	  of	  11p15	  
LOM	  patients	  (Gicquel	  et	  al.,	  2005).	  Serum	  IGF2	  levels,	  however,	  have	  been	  
shown	  to	  be	  normal	  in	  SRS	  patients	  (Binder	  et	  al.,	  2006)(Netchine	  et	  al.,	  2007),	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and	  it	  was	  proposed	  that	  the	  lack	  of	  changes	  in	  IGF2	  level	  in	  blood	  is	  due	  to	  IGF2	  
being	  regulated	  in	  a	  developmental-­‐	  and	  tissue-­‐specific	  way	  (Netchine	  et	  al.,	  
2007).	  In	  2014,	  Azzi	  and	  colleagues	  reported	  a	  significant	  correlation	  between	  
the	  methylation	  index	  of	  IGF2	  and	  fibroblast	  IGF2	  expression,	  supporting	  that	  
IGF2	  expression	  is	  regulated	  by	  methylation	  of	  the	  H19/IGF2:IG-­‐DMR.	  They	  also	  
showed	  that	  methylation	  levels	  of	  H19/IGF2:IG-­‐DMR	  may	  differ	  between	  cells	  
from	  different	  tissues,	  suggesting	  multiple	  mosaic,	  tissue-­‐specific	  epigenotypes	  
within	  individual	  patients	  (Azzi	  et	  al.,	  2014).	  	  
	  
It	  has	  also	  been	  reported	  that	  3.8%	  (3	  out	  of	  77)(Begemann	  et	  al.,	  2011),	  4%	  (3	  
out	  of	  74	  )(Azzi	  et	  al.,	  2009)	  and	  3	  out	  of	  6	  patients	  (Poole	  et	  al.,	  2013)	  of	  SRS	  
patients	  with	  confirmed	  11p15	  ICR1	  hypomethylation	  also	  have	  ICR2	  
hypomethylation,	  which	  is	  usually	  associated	  with	  BWS.	  	  
	  
Multi-­‐locus	  imprinting	  distubance	  (MLID)	  
	  
MLID,	  also	  known	  as	  multilocus	  loss	  of	  methylation	  (multilocus	  LOM),	  multilocus	  
methylation	  defects	  (MLMD),	  multilocus	  hypomethylation	  syndrome	  (MHS),	  
multilocus	  hypomethylation	  (MLH)	  or	  hypomethylation	  of	  multiple	  imprinted	  
loci	  (HIL),	  was	  described	  in	  SRS	  patients	  in	  2009	  by	  Azzi	  and	  colleagues	  (Azzi	  et	  
al.,	  2009),	  where	  7	  out	  of	  74	  SRS	  patients	  were	  discovered	  to	  have	  loss	  of	  
methylation	  at	  regions	  other	  than	  11p15.	  Turner	  and	  colleagues	  (Turner	  et	  al.,	  
2010)	  also	  found	  hypomethylation	  of	  multiple	  imprinted	  loci	  in	  2	  out	  of	  23	  
patients	  with	  11p15	  LOM.	  Later	  studies	  have	  found	  MLID	  in	  17%	  (Poole	  et	  al.,	  
2013),	  7.1%	  (Eggermann	  et	  al.,	  2014b)	  and	  11.4%	  (Azzi	  et	  al.,	  2015)	  of	  SRS	  
patients	  with	  11p15	  LOM.	  A	  genome-­‐wide	  study	  has	  detected	  73%	  of	  SRS	  
patients	  with	  additional	  aberrant	  methylation	  marks	  outside	  of	  11p15	  LOM	  
(Kannenberg	  et	  al.,	  2012).	  Azzi	  and	  colleagues	  (Azzi	  et	  al.,	  2009)	  did	  not	  find	  
significant	  differences	  in	  phenotype	  between	  11p15	  SRS	  patients	  with	  or	  without	  
MLID.	  Similar	  results	  were	  obtained	  by	  Poole	  and	  colleagues	  (Poole	  et	  al.,	  2013),	  
when	  they	  compared	  the	  clinical	  phenotypes	  of	  11p15	  LOM	  SRS	  patients	  with	  
and	  without	  MLID,	  and	  found	  no	  statistically	  significant	  difference	  between	  the	  
two	  groups,	  although	  developmental	  delay	  and	  atypical	  SRS	  features	  were	  more	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common	  in	  patients	  with	  MLID.	  The	  effect	  of	  MLID	  on	  the	  clinical	  phenotype	  of	  
SRS	  patients	  remains	  to	  be	  clarified.	  MLID	  is	  generally	  mosaic	  and	  imprinting	  
patterns	  vary	  between	  tissues,	  which	  may	  indicate	  that	  MLID	  arises	  post-­‐
fertilization	  (Mackay	  &	  Temple,	  2017).	  MLID	  has	  been	  shown	  to	  affect	  both	  
paternally	  and	  maternally	  imprinted	  genes,	  with	  loss	  and	  gain	  of	  methylation,	  
and	  in	  a	  mosaic	  pattern,	  suggesting	  origin	  in	  maintenance	  rather	  than	  
establishment	  of	  imprinting	  patterns	  (Eggermann,	  2014b).	  	  
	  
Copy	  number	  variations	  (CNVs)	  and	  other	  rare	  findings	  
	  
Many	  different	  CNVs	  have	  been	  reported	  in	  SRS,	  including	  various	  maternal	  
duplications	  of	  11p15	  (reviewed	  in	  Begemann	  et	  al.,	  2012	  and	  Fokstuen	  &	  
Kotzot,	  2014),	  duplication	  of	  7p12.1-­‐p13	  (Joyce	  et	  al.,	  1999),	  maternal	  
duplication	  of	  7p11.2-­‐p13	  (Monk	  et	  al.,	  2000),	  and	  many	  others	  at	  locations	  
outside	  chromosome	  7	  or	  11	  (Fokstuen	  &	  Kotzot,	  2014).	  In	  a	  review	  of	  all	  CNVs	  
reported	  in	  SRS	  patients	  up	  to	  2013,	  Fokstuen	  and	  Kotzot	  evaluated	  clinical	  
characteristics	  of	  the	  reported	  patients	  and	  concluded	  that	  most	  of	  the	  
chromosomal	  arrangements	  (except	  for	  duplication	  of	  11p15)	  do	  not	  justify	  SRS	  
diagnosis	  in	  the	  patients	  (Fokstuen	  &	  Kotzot,	  2014).	  	  
	  
In	  single	  cases	  of	  SRS	  or	  SRS-­‐like	  patients,	  mosaic	  UPD(11)mat	  (Bullman	  et	  al.,	  
2008),	  CDKN1C	  gain-­‐of-­‐function	  mutation	  in	  a	  family	  with	  maternally	  
transmitted	  SRS	  (Brioude	  et	  al.,	  2013)	  and	  paternally	  transmitted	  IGF2	  loss-­‐of-­‐
function	  mutation	  (Begemann	  et	  al.,	  2015)	  have	  been	  reported.	  	  
	  
Clinical	  SRS	  with	  unknown	  etiology	  
	  
A	  molecular	  cause	  can	  be	  identified	  in	  approximately	  60%	  of	  patients	  with	  SRS	  
(Wakeling	  et	  al.,	  2017).	  For	  those	  patients	  who	  fulfill	  the	  SRS	  criteria	  but	  have	  
negative	  results	  in	  molecular	  testing,	  the	  term	  clinical	  SRS	  is	  used.	  Alternative	  
terms	  for	  clinical	  SRS	  in	  literature	  include	  idiopathic	  SRS	  (Spengler	  et	  al.,	  2010)	  
and	  SRS	  of	  unexplained	  etiology	  (Kotzot,	  2008b).	  Identification	  of	  additional	  
molecular	  causes	  in	  clinically	  diagnosed	  SRS	  is	  important	  (Wakeling	  et	  al.,	  2017).	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Imprinted	  genes	  in	  normal	  growth	  
While	  the	  effect	  of	  imprinting	  defects	  on	  growth	  is	  clearly	  demonstrated	  in	  
imprinting	  disorders	  such	  as	  SRS,	  more	  subtle	  changes	  in	  imprinted	  genes	  have	  
been	  found	  to	  be	  associated	  with	  various	  growth	  parameters	  in	  the	  normal	  
population.	  Single	  nucleotide	  polymorphisms	  (SNPs)	  in	  the	  IGF2R,	  IGF2	  and	  H19	  
gene	  regions	  have	  been	  found	  to	  be	  associated	  with	  birth	  weight	  (Adkins	  et	  al.,	  
2010).	  A	  maternally	  inherited	  repeat	  sequence	  (RS1)	  of	  the	  imprinted	  PHLDA2	  
(pleckstrin	  homology	  like	  domain	  family	  A	  member	  2)	  causes	  an	  increase	  of	  
birth	  weight	  and	  head	  circumference	  (Ishida	  et	  al.,	  2012).	  The	  expression	  levels	  
of	  IGF2,	  IGF2R	  and	  H19	  in	  chorionic	  villus	  samples	  at	  approximately	  12	  weeks	  
gestation	  are	  correlated	  with	  crown-­‐rump	  length	  (Moore	  et	  al.,	  2015),	  
demonstrating	  growth	  regulation	  by	  imprinted	  genes	  early	  in	  development.	  A	  
SNP	  in	  the	  IGF2-­‐H19	  region	  is	  associated	  with	  birth	  length	  and	  adult	  height	  in	  a	  
parent-­‐of-­‐origin	  dependent	  manner	  (Benonisdottir	  et	  al.,	  2016),	  showing	  the	  
effect	  of	  imprinted	  genes	  on	  height	  during	  development	  as	  well	  as	  on	  the	  final	  
adult	  height	  in	  the	  normal	  population.	  
The	  study	  of	  the	  effect	  of	  imprinted	  genes	  on	  growth	  is	  complicated	  by	  the	  dual	  
role	  of	  imprinted	  gene	  expression	  as	  restrictive	  or	  promoting	  of	  growth.	  For	  
example,	  the	  observation	  of	  overexpression	  of	  the	  imprinted	  paternally	  
expressed	  10	  (PEG10)	  in	  IUGR	  (intrauterine	  growth	  restriction)	  placentas	  is	  
thought	  to	  result	  from	  a	  compensatory	  mechanism	  trying	  to	  protect	  a	  fetus	  from	  
growth	  restriction	  by	  promoting	  growth	  (Piedrahita,	  2011).	  
Environmental	  effects	  on	  imprinted	  genes	  and	  later	  disease	  development	  
Low	  birth	  weight	  is	  associated	  with	  many	  adult-­‐onset	  diseases,	  such	  as	  
hypertension	  (Huxley	  et	  al.,	  2000)	  and	  coronary	  artery	  disease	  (Barker	  et	  al.,	  
1989).	  Adverse	  environmental	  conditions	  during	  critical	  times	  of	  development	  
can	  predispose	  an	  individual	  to	  later	  development	  of	  disease.	  For	  example,	  
exposure	  to	  famine	  in	  fetal	  period	  and	  infancy	  is	  associated	  with	  a	  significantly	  
increased	  risk	  of	  hypertension	  and	  impaired	  glucose	  tolerance	  in	  adulthood	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(Hult	  et	  al.,	  2010).	  Preterm	  birth	  has	  also	  been	  linked	  with	  increased	  blood	  
pressure	  (de	  Jong	  et	  al.,	  2012),	  insulin	  resistance	  (Hofman	  et	  al.,	  2004)	  and	  
elevated	  plasma	  cortisol	  levels	  (Szathmari	  et	  al.,	  2000).	  	  
	  
The	  effects	  of	  environmental	  exposures	  may	  be	  mediated	  through	  epigenetic	  
mechanisms.	  These	  environmental	  factors	  occurring	  early	  in	  development	  can	  
cause	  changes	  in	  DNA	  methylation	  that	  persist	  throughout	  life	  (Heijmans	  et	  al.,	  
2008).	  In	  rats,	  maternal	  care	  during	  postnatal	  period	  affects	  stress	  responsivity	  
of	  the	  offspring	  through	  methylation	  changes	  in	  glucocorticoid	  receptor	  (GR)	  
promoter	  (Weaver	  et	  al.,	  2004).	  	  
	  
Imprinted	  genes,	  in	  particular,	  may	  be	  sensitive	  to	  environmental	  effects	  
(Waterland	  &	  Jirtle,	  2004).	  Increased	  methylation	  levels	  of	  the	  imprinted	  IGF2	  
have	  been	  reported	  in	  infants	  born	  to	  smokers	  compared	  to	  infants	  born	  to	  
nonsmokers	  (Murphy	  et	  al.,	  2012).	  DNA	  methylation	  levels	  of	  IGF2	  are	  also	  
reported	  lower	  in	  people	  who	  were	  prenatally	  exposed	  to	  famine	  during	  the	  
Dutch	  Hunger	  Winter	  in	  1944-­‐45	  (Heijmans	  et	  al.,	  2008).	  Also	  postnatal	  
exposures,	  such	  as	  early	  lead	  exposure	  in	  childhood,	  results	  in	  DNA	  methylation	  
changes	  in	  DMRs	  of	  the	  imprinted	  PEG3,	  IGF2/H19	  and	  PLAGL1/HYMAI	  (PLAG1	  
like	  zinc	  finger	  1/hydatidiform	  mole	  associated	  and	  imprinted)	  measured	  in	  
adulthood	  (Li	  et	  al.,	  2016).	  Assisted	  reproductive	  technologies	  have	  also	  been	  
associated	  with	  increased	  incidence	  of	  imprinting	  disorders	  (Allen	  &	  Reardon,	  
2005),	  but	  the	  evidence	  is	  not	  conclusive	  and	  the	  association	  could	  be	  at	  least	  in	  
part	  be	  explained	  by	  the	  reproductive	  disease	  of	  the	  parents	  (Pinborg	  et	  al.,	  
2016)	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AIMS	  OF	  THE	  STUDY	  
	  	  
This	  thesis	  aimed	  to	  explore	  the	  genetic	  and	  epigenetic	  factors	  contributing	  to	  
SRS	  and	  human	  growth,	  as	  well	  as	  epigenetic	  changes	  in	  preterm-­‐born	  very	  low	  
birth	  weight	  individuals.	  	  
	  
The	  specific	  aims	  were	  
	  
I	   to	  search	  for	  genomic	  aberrations	  in	  SRS	  and	  SRS-­‐like	  patients	  of	  
unknown	  etiology	  
	  
II	   to	  determine	  DNA	  methylation	  changes	  in	  the	  IGF2	  gene	  20	  years	  after	  
preterm	  birth	  at	  very	  low	  birth	  weight	  in	  individuals	  with	  elevated	  
cardiovascular	  risk	  factors	  
	  
III	  	   to	  find	  new	  imprinted	  genes	  by	  using	  DNA	  methylation	  differences	  in	  
UPD(7)mat	  patients	  compared	  to	  controls	  and	  UPD(7)pat	  
	  
IV	   to	  find	  new,	  shared	  DNA	  methylation	  changes	  among	  different	  subtypes	  
of	  SRS	  and	  to	  find	  out	  whether	  those	  changes	  are	  associated	  with	  height	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MATERIALS	  AND	  METHODS	  	  
Patients	  	  
Study	  I:	  22	  patients	  with	  SRS	  were	  included	  in	  the	  study.	  10	  of	  the	  SRS	  patients	  
had	  11p15	  LOM	  and	  12	  had	  clinical	  SRS.	  Also	  parents	  of	  the	  children	  were	  
included	  in	  the	  study.	  The	  patients	  were	  recruited	  mainly	  from	  the	  Hospital	  for	  
Children	  and	  Adolescents,	  Helsinki	  University	  Central	  Hospital,	  Finland.	  
	  
Study	  II:	  158	  young	  adults	  born	  preterm	  at	  very	  low	  birth	  weight	  (VLBW)	  were	  
from	  the	  Helsinki	  Study	  of	  Very	  Low	  Birth	  Weight	  Adults	  that	  includes	  patients	  
who	  were	  born	  preterm	  at	  very	  low	  birth	  weight	  and	  were	  treated	  at	  the	  
Neonatal	  intensive	  care	  unit	  of	  the	  Children’s	  Hospital	  of	  the	  Helsinki	  University	  
Central	  Hospital.	  The	  161	  control	  subjects	  were	  matched	  for	  sex,	  age	  and	  birth	  
hospital	  and	  were	  born	  at	  term	  with	  birth	  weight	  more	  than	  -­‐2SD.	  The	  age	  range	  
for	  the	  individuals	  studied	  at	  the	  time	  when	  DNA	  methylation	  was	  measured	  was	  
from	  18	  to	  27	  years.	  
	  
Study	  III:	  9	  UPD(7)mat	  patients,	  including	  one	  patient	  with	  segmental	  
UPD(7q31-­‐qter),	  ten	  controls	  and	  one	  individual	  with	  UPD(7)pat	  were	  studied.	  
Ten	  unrelated	  individuals	  of	  normal	  height	  were	  used	  as	  controls.	  The	  SRS	  
patients	  were	  recruited	  from	  the	  Hospital	  for	  Children	  and	  Adolescents,	  Helsinki	  
University	  Central	  Hospital,	  Finland.	  Additionally	  three	  patients	  were	  referred	  
from	  the	  Oulu	  University	  Central	  Hospital	  and	  one	  from	  the	  Päijät-­‐Häme	  Central	  
Hospital,	  Finland.	  Samples	  for	  parent-­‐of-­‐origin	  allele-­‐specific	  expression	  analysis	  
were	  obtained	  from	  nine	  parent-­‐child	  trios	  from	  the	  growth	  restriction	  study	  
cohort,	  in	  which	  the	  child	  of	  the	  trio	  had	  previously	  been	  confirmed	  not	  to	  have	  
UPD.	  	  
	  
Study	  IV:	  44	  SRS	  patients,	  of	  whom	  21	  patients	  had	  11p15	  LOM,	  10	  patients	  had	  
UPD(7)mat	  and	  13	  patients	  had	  clinical	  SRS	  (i.e.	  no	  findings	  of	  11p15	  LOM	  or	  
UPD(7)mat)	  were	  studied.	  One	  of	  the	  10	  UPD(7)mat	  patients	  had	  segmental	  
UPD(7q31-­‐qter)mat.	  One	  UPD(7)pat	  sample	  was	  also	  included.	  The	  control	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samples	  were	  obtained	  from	  ten	  adults	  of	  normal	  height	  and	  six	  additional	  
samples	  from	  adults	  that	  were	  healthy	  blood	  donors.	  39	  patients	  with	  severe	  
growth	  restriction	  of	  unknown	  etiology	  (SGR)	  were	  included	  in	  a	  targeted	  
analysis	  of	  HOXA4	  hypomethylation.	  Majority	  of	  the	  SGR	  patients	  were	  born	  SGA	  
and	  all	  of	  them	  had	  postnatal	  growth	  restriction.	  The	  SRS	  and	  SGR	  patients	  were	  
recruited	  mainly	  from	  the	  Hospital	  for	  Children	  and	  Adolescents,	  Helsinki	  
University	  Central	  Hospital,	  Finland.	  Methylation	  data	  from	  227	  healthy	  children	  
of	  the	  BAMSE	  (Swedish	  abbreviation	  for	  Children,	  Allergy,	  Milieu,	  Stockholm,	  
Epidemiology)	  cohort,	  a	  birth	  cohort	  of	  children	  born	  in	  Stockholm	  between	  
1994	  and	  1996),	  was	  used	  to	  perform	  correlation	  analysis	  of	  height	  and	  HOXA4	  
methylation	  level.	  	  
	  
The	  studies	  were	  conducted	  in	  accordance	  with	  the	  principles	  of	  the	  declaration	  
of	  Helsinki.	  Informed	  consent	  was	  obtained	  from	  all	  participants.	  The	  studies	  
were	  approved	  by	  the	  appropriate	  ethical	  review	  boards:	  the	  Ethical	  Review	  
Board	  of	  the	  Hospital	  for	  Children	  and	  Adolescents,	  Helsinki	  University	  Central	  
Hospital,	  Helsinki,	  Finland,	  the	  Ethics	  Committee	  of	  the	  Helsinki	  and	  Uusimaa	  
Hospital	  District,	  Finland	  and	  the	  Ethical	  Review	  Board	  North	  at	  Karolinska	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Sample	  processing	  
DNA	  extraction	  (Studies	  I,	  II,	  III	  and	  IV)	  
DNA	  from	  the	  participants’	  whole	  blood	  samples	  was	  extracted	  using	  FlexiGene	  
DNA	  Kit	  (Qiagen)	  or	  QIAamp	  DNA	  Blood	  Maxi	  Kit	  (Qiagen).	  	  
Bisulfite	  conversion	  (Studies	  II,	  III	  and	  IV)	  
Bisulfite	  conversion	  of	  DNA	  was	  performed	  in	  order	  to	  prepare	  the	  samples	  for	  
DNA	  methylation	  analysis	  with	  EpiTYPER,	  pyrosequencing	  and	  Illumina	  450K	  
HumanMethylation	  Bead	  chip	  in	  studies	  II,	  III	  and	  IV.	  Bisulfite	  treatment	  
converts	  unmethylated	  cytosine	  to	  uracil,	  but	  leaves	  5-­‐methylcytosine	  
unaffected,	  allowing	  distinction	  between	  the	  unmethylated	  and	  methylated	  
cytosines.	  500	  ng	  of	  DNA	  was	  converted	  with	  the	  EZ-­‐96	  Methylation	  Kit	  (Zymo	  
research	  corporation)	  for	  studies	  II,	  III	  and	  IV.	  The	  EpiTect	  Bisulfite	  Kit	  (Qiagen)	  
was	  used	  for	  bisulfite	  conversion	  of	  2	  ug	  of	  DNA	  for	  the	  pyrosequencing	  study	  in	  
Study	  III.	  
RNA	  extraction	  (Study	  III)	  
Whole	  blood	  was	  collected	  into	  PAXgene	  Blood	  RNA	  tubes	  (PreAnalytix,	  GmbH)	  
and	  RNA	  was	  extracted	  using	  the	  PAXgene	  Blood	  miRNA	  Kit	  (PreAnalytix,	  
GmbH).	  Bioanalyzer	  (Agilent	  Technologies)	  was	  used	  to	  check	  the	  quality	  of	  the	  
RNA	  samples.	  RIN	  (RNA	  integrity	  number)	  indicates	  the	  level	  of	  quality	  of	  the	  
RNA	  sample.	  All	  of	  the	  samples	  had	  RIN	  above	  8	  and	  were	  therefore	  of	  sufficient	  
quality	  to	  be	  included	  in	  the	  analyses.	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Methods	  for	  studying	  genetics	  
Affymetrix	  genotyping	  (Study	  I)	  
In	  addition	  to	  genotyping,	  Affymetrix	  genotyping	  arrays	  can	  be	  used	  for	  both	  
DNA	  copy	  number	  analysis	  and	  detection	  of	  UPDs.	  The	  GeneChip	  Mapping	  250K	  
Sty	  array	  enables	  study	  of	  238	  000	  SNPs	  distributed	  across	  the	  genome.	  The	  
array	  contains	  allele-­‐specific	  oligonucleotide	  hybridization	  probes,	  located	  at	  
specific	  positions	  on	  the	  array	  that	  are	  complementary	  to	  the	  sequence	  of	  the	  
studied	  SNP	  region.	  The	  protocol	  includes	  digestion	  of	  genomic	  DNA	  with	  a	  
restriction	  enzyme	  Sty	  I	  (a	  restriction	  enzyme	  purified	  from	  E.	  coli),	  ligation	  of	  
adaptors	  to	  the	  ends	  of	  the	  restriction	  fragments,	  PCR	  (polymerase	  chain	  
reaction)	  amplification	  of	  the	  fragments,	  fragmentation	  of	  the	  PCR	  products	  with	  
DNAse	  I	  (deoxyribonuclease	  I),	  biotinylation	  of	  the	  fragments	  and	  hybridization	  
of	  the	  fragments	  to	  the	  arrays.	  When	  the	  arrays	  are	  scanned,	  genotypes	  are	  
determined	  based	  on	  hybridization	  signal	  intensities	  from	  allele-­‐specific	  probes	  
(Matsuzaki	  et	  al.,	  2004).	  Copy	  number	  changes	  can	  be	  evaluated	  by	  comparing	  
the	  signal	  intensity	  values	  against	  a	  reference	  set	  of	  data	  (Winchester	  et	  al.,	  
2009).	  The	  array	  was	  used	  in	  Study	  I	  to	  detect	  copy	  number	  changes	  in	  SRS	  and	  
SRS-­‐like	  patients.	  	  
	  
Polymerase	  chain	  reaction	  (PCR)	  
PCR	  is	  a	  technique	  by	  which	  a	  small	  amount	  of	  a	  specific	  target	  sequence	  of	  DNA	  
can	  be	  amplified.	  It	  requires	  two	  oligonucleotide	  fragments	  (primers)	  that	  are	  
complementary	  to	  the	  target	  DNA	  sequence.	  Each	  cycle	  of	  different	  temperatures	  
causes	  separation	  of	  the	  DNA	  strands,	  annealing	  of	  primers	  to	  the	  
complementary	  sequence	  and	  an	  extension	  by	  DNA	  polymerase,	  resulting	  in	  
doubling	  of	  the	  amount	  of	  DNA.	  As	  the	  cycles	  are	  repeated,	  the	  target	  sequence	  
accumulates	  exponentially,	  approximately	  2n,	  n	  being	  the	  number	  of	  cycles	  (Saiki	  
et	  al.,	  1988).	  PCR	  was	  used	  in	  all	  four	  studies.	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Methods	  for	  studying	  epigenetics	  
Pyrosequencing	  (Study	  III)	  
Pyrosequencing	  technology	  can	  be	  used	  for	  studying	  DNA	  methylation,	  among	  
other	  uses.	  A	  several	  hundred	  base	  pair	  segment	  is	  PCR	  amplified,	  with	  one	  
primer	  biotinylated.	  The	  biotinylated	  PCR	  products	  are	  immobilized	  onto	  
streptavidin-­‐coated	  sepharose	  beads.	  After	  separation	  of	  the	  strands,	  the	  
biotinylated	  single	  strand	  hybridizes	  with	  a	  sequencing	  primer	  and	  DNA	  
polymerase	  catalyzes	  the	  addition	  of	  dNTPs	  (deoxyribonucleotide	  
triphosphates).	  Each	  addition	  is	  accompanied	  by	  a	  release	  of	  pyrophosphate,	  
which	  through	  several	  reactions	  causes	  emission	  of	  visible	  light	  that	  is	  detectable	  
in	  a	  charge	  coupled	  device	  camera.	  Nucleotide	  sequence	  can	  be	  detected	  from	  
the	  signal	  peaks	  (reviewed	  in	  Schock	  &	  Traeger,	  2011).	  In	  Study	  III,	  
pyrosequencing	  was	  used	  to	  validate	  the	  methylation	  status	  of	  specific	  regions	  
by	  first	  converting	  the	  samples	  by	  bisulfite	  treatment.	  The	  technology	  provides	  a	  
methylation	  percentage	  for	  each	  individual	  CpG	  site.	  	  
	  
EpiTYPER	  (Studies	  II	  and	  IV)	  
EpiTYPER	  technology	  enables	  the	  study	  of	  DNA	  methylation	  of	  CpG	  sites	  within	  
designed	  amplicons	  of	  regions	  of	  interest.	  EpiTYPER	  requires	  bisulfite	  treatment	  
of	  the	  DNA	  samples.	  Unmethylated	  cytosines	  are	  converted	  into	  uracils	  and	  
methylated	  cytosines	  remain	  unchanged.	  PCR	  is	  run,	  after	  which	  the	  PCR	  product	  
is	  transcribed	  into	  an	  RNA	  transcript	  and	  cleaved	  base	  specifically	  by	  an	  
endonuclease.	  The	  cleavage	  products	  are	  analyzed	  by	  matrix	  assisted	  laser	  
desorption/ionization	  –	  time	  of	  flight	  mass	  spectrometry	  (MALDI-­‐TOF	  MS).	  The	  
mass	  spectrometer	  differentiates	  between	  methylated	  and	  unmethylated	  CpGs	  
by	  detecting	  the	  mass	  difference	  of	  16	  Da	  (Daltons)	  per	  CpG	  site	  (G	  vs.	  A).	  
Relative	  methylation	  level	  can	  be	  calculated	  by	  comparing	  the	  intensities	  of	  the	  
signals	  coming	  from	  the	  methylated	  and	  unmethylated	  cleavage	  products.	  Each	  
analyzed	  CpG	  unit	  may	  contain	  one	  or	  more	  CpG	  sites.	  When	  there	  are	  multiple	  
CpGs	  in	  one	  CpG	  unit,	  the	  mass	  difference	  detected	  by	  the	  mass	  spectrometer	  
	   44	  
will	  be	  in	  multiples	  of	  16	  Da	  (Ehrich	  et	  al.,	  2005).	  In	  Studies	  II	  and	  IV,	  EpiTYPER	  
was	  used	  for	  targeted	  methylation	  studies	  of	  regions	  of	  interest.	  	  
	  
Genome-­‐wide	  methylation	  analysis	  with	  Illumina	  450K	  BeadChip	  assay	  
(Studies	  III	  and	  IV)	  
The	  Illumina	  Human	  Methylation	  BeadChip	  is	  a	  technology	  that	  enables	  the	  
study	  of	  DNA	  methylation	  of	  more	  than	  450	  000	  individual	  CpG	  sites	  across	  the	  
genome,	  covering	  99%	  of	  RefSeq	  genes	  and	  96%	  of	  CpG	  islands.	  The	  BeadChip	  
requires	  use	  of	  bisulfite-­‐converted	  DNA.	  Two	  assay	  types,	  Infinium	  I	  and	  
Infinium	  II,	  are	  included	  in	  the	  microarray.	  Infinium	  I	  assay	  consists	  of	  two	  bead	  
types,	  one	  for	  methylated	  CpG	  and	  one	  for	  unmethylated	  CpG.	  In	  Infinium	  II	  
assay,	  one	  bead	  type	  corresponds	  to	  each	  CpG	  locus	  and	  the	  methylation	  state	  is	  
detected	  by	  single	  base	  extension.	  In	  the	  assay	  protocol,	  bisulfite	  treated	  samples	  
are	  whole	  genome	  amplified,	  fragmented	  and	  hybridized	  to	  the	  bead	  chips.	  After	  
extension	  and	  staining	  steps,	  the	  BeadChips	  are	  imaged.	  Methylation	  level	  is	  
calculated	  based	  on	  the	  intensities	  of	  the	  methylated	  and	  the	  unmethylated	  
signal	  (Bibikova	  et	  al.,	  2011).	  In	  studies	  III	  and	  IV,	  the	  Illumina	  450K	  BeadChip	  
was	  used	  to	  study	  genome-­‐wide	  methylation	  changes	  in	  UPD	  patients	  and	  SRS	  
subgroups.	  	  
Methods	  for	  studying	  gene	  expression	  and	  copy	  number	  changes	  
Quantitative	  real-­‐time	  PCR	  (Study	  I	  and	  III)	  
Quantitative	  real-­‐time	  PCR	  (qPCR)	  is	  a	  technique	  based	  on	  real-­‐time	  monitoring	  
of	  each	  cycle	  of	  PCR.	  qPCR	  can	  be	  used,	  for	  example,	  to	  study	  the	  expression	  level	  
of	  genes	  or	  to	  detect	  CNVs	  in	  genomic	  DNA	  samples.	  In	  general,	  qPCR	  can	  be	  
performed	  using	  either	  the	  fluorescent	  dye	  SYBR-­‐Green,	  that	  binds	  to	  double-­‐
stranded	  DNA	  (Ponchel	  et	  al.,	  2003),	  or	  TaqMan	  assays,	  that	  use	  a	  hybridization	  
probe	  labeled	  with	  two	  different	  fluorescent	  dyes	  (Heid	  et	  al.,	  1996).	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SYBR-­‐Green	  based	  qPCR	  was	  used	  in	  Study	  I	  to	  verify	  CNVs	  that	  had	  been	  
detected	  with	  the	  Affymetrix	  250K	  genotyping	  array.	  PCR	  amplicons	  located	  
within	  the	  deleted	  or	  duplicated	  regions	  were	  used	  to	  verify	  the	  copy	  number	  
change	  by	  comparing	  the	  CT	  values	  of	  the	  patient	  DNA	  samples	  to	  the	  CT	  values	  of	  
the	  control	  DNA	  samples,	  a	  method	  originally	  described	  by	  Weksberg	  and	  
colleagues	  (Weksberg	  et	  al.,	  2005).	  
	  
Taqman	  gene	  expression	  assays	  were	  used	  in	  Study	  III	  to	  quantify	  expression	  
levels	  of	  genes	  that	  had	  been	  identified	  as	  potential	  imprinted	  genes,	  and	  were	  
therefore	  predicted	  to	  show	  significant	  gene	  expression	  differences	  between	  
UPD(7)mat	  samples,	  UPD(7)pat	  sample	  and	  controls.	  	  
	  
Results	  of	  the	  qPCR	  experiments	  were	  calculated	  with	  the	  comparative	  CT	  
method	  (Schmittgen	  and	  Livak,	  2008).	  
Parent-­‐of-­‐origin	  allele-­‐specific	  expression	  analysis	  (Study	  III)	  
Parent-­‐child	  trios	  can	  be	  used	  to	  verify	  that	  an	  allele	  is	  being	  expressed	  from	  
only	  one	  parental	  chromosome.	  The	  requirement	  is	  to	  obtain	  DNA	  samples	  from	  
a	  child	  and	  his/her	  two	  parents,	  and	  an	  RNA	  sample	  from	  the	  child.	  Individuals	  
with	  UPDs	  of	  the	  studied	  region	  must	  be	  excluded	  from	  the	  analysis.	  Monoallelic	  
expression	  can	  be	  tested	  by	  using	  SNPs	  that	  are	  located	  in	  an	  exon	  of	  the	  studied	  
gene.	  SNPs	  that	  are	  heterozygous	  in	  the	  child	  and	  homozygous	  in	  at	  least	  one	  
parent	  can	  be	  used	  in	  the	  analysis.	  The	  child’s	  RNA	  is	  converted	  into	  cDNA	  
(complementary	  DNA)	  and	  sequenced.	  If	  the	  child’s	  cDNA	  confirms	  monoallelic	  
expression,	  maternal	  or	  paternal	  specific	  expression	  of	  the	  gene	  may	  be	  deduced	  
by	  looking	  at	  the	  parental	  genotypes.	  The	  described	  strategy	  was	  used	  in	  Study	  
III	  to	  verify	  parent-­‐of-­‐origin	  allele-­‐specific	  expression	  of	  potential	  imprinted	  
genes.	  	  	  
	   46	  
Data	  analysis,	  statistical	  methods	  and	  data	  visualization	  
Data	  analysis	  for	  the	  Illumina	  450K	  BeadChip	  (Study	  III	  and	  IV)	  
In	  Study	  III,	  the	  raw	  data	  was	  analyzed	  using	  the	  BioConductor	  package	  lumi	  in	  R	  
v.	  2.13	  (Du	  et	  al.,	  2008).	  Adjustments	  for	  color	  channel	  imbalance	  and	  
background	  noise	  were	  made,	  and	  the	  data	  was	  normalized	  using	  the	  quantile	  
method.	  Differential	  methylation	  for	  each	  probe	  was	  calculated	  by	  a	  linear	  model	  
and	  by	  pair-­‐wise	  comparisons	  by	  empirical	  Bayes	  t-­‐test	  on	  the	  normalized	  M-­‐
values	  (Smyth,	  2005).	  The	  M-­‐values	  are	  useful	  for	  assessing	  especially	  high	  and	  
low	  methylation	  levels.	  
	  
In	  Study	  IV,	  	  the	  raw	  data	  was	  analyzed	  using	  the	  minfi	  package	  (Aryee	  et	  al.,	  
2014).	  The	  data	  was	  normalized	  using	  the	  subset-­‐quantile	  within	  array	  
normalization	  (SWAN)	  method	  (Maksimovic	  et	  al.,	  2012).	  All	  probes	  that	  
overlapped	  with	  known	  SNPs	  and	  those	  with	  reported	  cross-­‐hybridization	  
problems	  were	  removed	  from	  the	  analysis.	  The	  ComBat	  method	  was	  used	  to	  
remove	  batch	  effects	  (Johnson	  et	  al.,	  2007).	  CpGs	  with	  differential	  methylation	  
were	  obtained	  by	  using	  linear	  models	  and	  pair-­‐wise	  comparisons	  by	  empirical	  
Bayes	  t-­‐test	  using	  the	  limma	  package	  (Smyth,	  2005).	  Further	  analysis	  proceeded	  
with	  CpG	  sites	  that	  had	  a	  p-­‐value	  <	  0.05	  after	  Benjamini	  and	  Hochberg	  correction	  
for	  multiple	  testing.	  	  
Filtering	  the	  genome-­‐wide	  methylation	  data	  (Study	  III	  and	  IV)	  
In	  order	  to	  best	  utilize	  the	  genome-­‐wide	  methylation	  data,	  it	  was	  necessary	  to	  
design	  a	  filtering	  approach	  by	  which	  it	  is	  possible	  to	  obtain	  information	  on	  
specific	  changes	  in	  the	  methylation	  landscape.	  	  
	  
In	  Study	  III,	  a	  filtering	  system	  was	  created	  to	  detect	  differentially	  methylated	  
regions	  on	  chromosome	  7.	  The	  filtering	  system	  was	  based	  on	  three	  criteria	  that	  
were	  assumed	  to	  be	  true	  for	  differentially	  methylated	  regions:	  1)	  the	  median	  
methylation	  levels	  for	  UPD(7)mat,	  controls	  and	  UPD(7)pat	  for	  a	  CpG	  were	  either	  
in	  ascending	  or	  descending	  order,	  2)	  differential	  methylation	  between	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UPD(7)mat	  and	  controls	  was	  statistically	  significant	  (p<0,05)	  and	  3)	  there	  were	  
at	  least	  three	  adjacent	  probes	  that	  passed	  criteria	  1	  and	  2.	  	  
	  
In	  Study	  IV,	  a	  filtering	  system	  was	  created	  in	  order	  to	  search	  for	  common	  
differentially	  methylated	  regions	  among	  all	  three	  subgroups	  of	  SRS.	  This	  filtering	  
system	  fulfilled	  two	  criteria:	  the	  methylation	  level	  for	  each	  SRS	  subgroup	  was	  
statistically	  significantly	  different	  from	  the	  controls	  for	  a	  given	  CpG	  and	  there	  
were	  at	  least	  three	  such	  CpG	  sites	  adjacent	  to	  each	  other.	  	  
	  
In	  both	  studies,	  the	  filtering	  system	  was	  designed	  to	  detect	  stretches	  of	  
differentially	  methylated	  CpGs,	  similar	  to	  the	  DMRs	  of	  the	  known	  imprinted	  
genes,	  rather	  than	  single	  differentially	  methylated	  CpGs.	  	  
Data	  analysis	  for	  Affymetrix	  array	  (Study	  II)	  
Affymetrix	  GeneChip	  Genotyping	  Analysis	  Software	  (GTYPE	  4.1)	  was	  used	  for	  
determining	  genotypes,	  average	  heterozygosity	  estimates	  and	  pedigree	  checks.	  
SNPTrio,	  an	  analysis	  tool	  for	  SNP	  data	  from	  trios,	  was	  used	  for	  identifying	  
Mendelian	  inconsistencies	  (Ting	  et	  al.,	  2007).	  Copy	  Number	  Analyzer	  for	  
Affymetrix	  GeneChip	  Mapping	  2.0	  (CNAG	  2.0)	  was	  used	  for	  identifying	  copy	  
number	  variation	  and	  loss-­‐of-­‐heterozygosity	  regions	  (Nannya	  et	  al.,	  2005).	  Also	  
the	  Aroma.Affymetrix	  package	  in	  R	  was	  used	  to	  identify	  copy	  number	  variations	  
(Bengtsson	  et	  al.,	  2008).	  	  
Methylation	  status	  of	  individuals	  (Study	  IV)	  
Normal	  methylation	  level	  for	  each	  HOXA4	  CpG	  of	  the	  differentially	  methylated	  
area	  was	  determined	  by	  calculating	  standard	  deviation	  of	  the	  methylation	  values	  
of	  the	  16	  control	  samples.	  SD	  value	  for	  each	  individual	  patient	  was	  calculated	  
based	  on	  the	  standard	  deviation	  of	  the	  controls.	  A	  value	  <-­‐2SD	  indicates	  a	  
hypomethylated	  CpG.	  A	  patient	  was	  considered	  HOXA4	  hypomethylated	  when	  at	  
least	  two-­‐thirds	  of	  the	  CpG	  sites	  in	  the	  differentially	  methylated	  area	  of	  HOXA4	  
were	  <-­‐2SD.	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Data	  visualization	  (Study	  III)	  
The	  Integrated	  Genome	  Browser	  (IGB)	  (Freese	  et	  al.,	  2016)	  was	  used	  to	  visualize	  
methylation	  patterns	  of	  the	  genome-­‐wide	  methylation	  data	  and	  to	  integrate	  
information	  such	  as	  location	  of	  CGIs,	  genes	  and	  TSSs	  that	  overlapped	  with	  
specific	  CpGs.	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RESULTS	  AND	  DISCUSSION	  
Study	  I	  
Genomic	  aberrations	  in	  SRS	  
A	  genome-­‐wide	  Affymetrix	  genotyping	  array	  was	  used	  to	  study	  potential	  
genomic	  aberrations	  in	  SRS	  patients	  with	  11p15	  LOM	  and	  clinical	  SRS	  (unknown	  
etiology).	  Four	  of	  the	  12	  SRS	  patients	  with	  unknown	  etiology	  were	  termed	  SRS-­‐
like	  due	  to	  fewer	  fulfilled	  clinical	  criteria.	  None	  of	  the	  patients	  had	  UPD(7)mat.	  	  
	  
Altogether	  60	  CNVs	  were	  identified	  with	  CNAG	  2.0	  and	  687	  CNVs	  by	  the	  more	  
sensitive	  Aroma.Affymetrix	  program.	  When	  combining	  the	  data	  from	  these	  two	  
programs,	  a	  list	  of	  33	  CNVs	  was	  obtained	  that	  included	  only	  CNVs	  reported	  by	  
both	  programs.	  The	  largest	  CNVs	  were	  identified	  in	  3	  out	  of	  12	  patients	  with	  
clinical	  SRS:	  a	  heterozygous	  deletion	  of	  chromosome	  15q26.3	  including	  IGF1R	  
(2,6	  Mb),	  a	  22q11.21-­‐q11.22	  deletion	  (1,1	  Mb)	  and	  a	  pseudoautosomal	  Xp22.33	  
duplication	  (2,7	  Mb).	  All	  three	  CNVs	  were	  confirmed	  with	  qPCR	  analysis	  and	  
there	  were	  no	  CNVs	  reported	  in	  DGV	  (Database	  of	  Genomic	  Variants)	  that	  would	  
have	  entirely	  covered	  these	  regions.	  	  
	  
Large	  CNVs	  on	  14q11.2,	  15q11.2	  and	  17q21.3	  occurred	  in	  multiple	  patients,	  but	  
these	  regions	  are	  known	  to	  carry	  segmental	  duplications	  and	  these	  CNVs	  can	  be	  
considered	  as	  normal	  variation	  between	  individuals.	  A	  search	  for	  CNVs	  that	  were	  
found	  in	  at	  least	  three	  SRS	  patients,	  but	  had	  not	  been	  reported	  to	  DGV,	  yielded	  10	  
regions	  containing	  known	  genes:	  CNTNAP2	  (contactin	  associated	  protein	  like	  2),	  
RERG	  (RAS	  like	  estrogen	  regulated	  growth	  inhibitor),	  AGPAT5	  (1-­‐acylglycerol-­‐3-­‐
phosphate	  O-­‐acyltransferase	  5),	  CSRP1	  (cysteine	  and	  glycine	  rich	  protein	  1),	  
ITGB8	  (integrin	  subunit	  beta	  8),	  SPOCK1	  (SPARC	  (osteonectin),	  cwcv	  and	  kazal	  
like	  domains	  proteoglycan	  1),	  TFCP2	  (transcription	  factor	  CP2),	  FRMD6	  (FERM	  
domain	  containing	  6),	  POU6F1	  (POU	  class	  6	  homeobox	  1)	  and	  SH3MD4	  (SH3	  
domain	  containing	  ring	  finger	  3).	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LOH	  regions	  were	  determined	  in	  order	  to	  search	  for	  regions	  potentially	  
corresponding	  to	  recessive	  disease	  alleles.	  Two	  regions	  of	  LOH,	  8p11.21-­‐q11.23	  
and	  13q31-­‐q32,	  corresponded	  to	  regions	  previously	  reported	  in	  patients	  with	  
SRS-­‐like	  features.	  The	  8p11.21-­‐q11.23	  LOH	  found	  in	  a	  SRS	  patient	  of	  unknown	  
etiology	  overlapped	  with	  a	  deletion	  of	  8q11-­‐q12	  reported	  in	  a	  patient	  with	  SRS-­‐
like	  features	  (Schinzel	  et	  al.,	  1994).	  The	  13q31-­‐q32	  LOH	  region	  in	  another	  
patient	  with	  SRS	  of	  unknown	  etiology	  corresponded	  to	  one	  reported	  patient	  with	  
SRS-­‐like	  features	  and	  a	  chromosome	  13q	  deletion	  (Wahlström	  et	  al.,	  1993).	  The	  
13q31-­‐q32	  LOH	  regions	  spans	  three	  genes:	  GPC5	  (glypican	  5),	  GPC6	  (glypican	  6)	  
and	  SOX21	  (SRY-­‐box	  21).	  The	  glypicans	  are	  a	  family	  of	  glycoproteins,	  which	  may	  
play	  a	  role	  in	  the	  control	  of	  cell	  division	  and	  growth	  regulation.	  Interestingly,	  one	  
member	  of	  this	  family,	  GPC3,	  causes	  Simpson-­‐Golabi-­‐Behmel	  overgrowth	  
syndrome	  (Cottereau	  et	  al.,	  2013).	  	  
	  
All	  of	  the	  three	  largest	  CNV	  regions	  (15q26.3	  heterozygous	  deletion	  including	  
IGF1R	  (2,6	  Mb),	  a	  22q11.21-­‐q11.22	  deletion	  (1,1	  Mb)	  and	  a	  pseudoautosomal	  
Xp22.33	  duplication	  (2,7	  Mb)	  correspond	  to	  reported	  cases	  of	  growth	  restriction.	  
15q	  deletions	  including	  the	  IGF1R	  gene	  have	  been	  characterized	  with	  pre-­‐	  and	  
postnatal	  growth	  restriction,	  microcephaly,	  developmental	  delay,	  skeletal	  
abnormalities	  and	  dysmorphic	  facial	  features	  (Rudaks	  et	  al.,	  2011),	  while	  
increased	  dosage	  of	  15q	  results	  in	  overgrowth	  (Tatton-­‐Brown,	  2009).	  The	  
patient	  with	  15q26.3	  deletion	  had	  pre-­‐	  and	  postnatal	  growth	  restriction,	  
developmental	  delay,	  triangular	  face	  and	  micrognathia,	  but	  had	  relative	  
macrocephaly	  instead	  of	  the	  microcephaly	  that	  is	  typical	  in	  IGF2R	  deletion	  
patients.	  The	  patient	  with	  a	  22q11.21-­‐q11.22	  deletion	  presented	  with	  pre-­‐	  and	  
postnatal	  growth	  restriction,	  among	  other	  features.	  22q11.2	  deletion	  syndrome,	  
with	  a	  heterogeneous	  clinical	  presentation,	  is	  associated	  with	  intrauterine	  
growth	  restriction	  in	  4%	  of	  the	  patients	  and	  short	  stature	  in	  15%	  of	  the	  patients	  
(McDonald-­‐McGinn	  et	  al.,	  2015).	  The	  patient	  with	  pseudoautosomal	  Xp22.33	  
duplication	  including	  the	  short	  stature	  homeobox	  (SHOX)	  gene	  presented	  with	  
both	  pre-­‐	  and	  postnatal	  growth	  restriction	  and	  had	  no	  response	  to	  GH	  treatment.	  
Although	  SHOX	  mutations	  and	  deletions	  are	  typically	  associated	  with	  short	  
stature,	  also	  SHOX	  duplications	  have	  been	  described	  in	  patients	  with	  idiopathic	  
	   52	  
short	  stature	  (ISS),	  including	  a	  report	  of	  six	  ISS	  patients	  with	  SHOX	  duplications	  
(Benito-­‐Sanz,	  2011).	  	  
Study	  II	  
Methylation	  changes	  in	  individuals	  born	  preterm	  
CpGs	  of	  the	  IGF2	  gene	  were	  studied	  in	  adults	  born	  preterm	  at	  very	  low	  birth	  
weight.	  These	  individuals	  had	  elevated	  levels	  of	  cardiovascular	  disease	  risk	  
factors	  in	  comparison	  to	  controls	  born	  at	  term.	  Individuals	  who	  are	  born	  
preterm	  at	  very	  low	  birth	  weight	  have	  a	  higher	  risk	  for	  adult-­‐onset	  disease,	  and	  
these	  risks	  might	  be	  carried	  through	  epigenetic	  changes	  of	  imprinted	  genes.	  The	  
aim	  of	  Study	  I	  was	  to	  test	  for	  the	  presence	  of	  epigenetic	  changes	  in	  IGF2.	  We	  
found	  that	  the	  difference	  in	  methylation	  level	  of	  one	  CpG	  in	  IGF2	  gene	  was	  
statistically	  significant	  between	  individuals	  born	  preterm	  at	  VLBW	  and	  controls,	  
20	  years	  after	  birth.	  The	  difference	  was	  significant	  after	  correction	  for	  multiple	  
variables	  that	  could	  have	  affected	  the	  results,	  such	  as	  plate	  number,	  sex,	  age,	  
BMI,	  mother’s	  smoking	  during	  pregnancy,	  age	  of	  parents,	  mother’s	  BMI	  before	  
pregnancy	  and	  highest	  education	  of	  either	  parent.	  The	  difference	  was	  around	  
2%,	  and	  also	  the	  other	  sites	  in	  the	  same	  area	  had	  a	  similar	  trend	  showing	  lower	  
methylation	  in	  the	  subjects	  compared	  to	  controls.	  The	  results	  were	  similar	  to	  the	  
Dutch	  famine	  study	  (Heijmans	  et	  al.,	  2008),	  where	  people	  exposed	  to	  early	  
nutritional	  deprivation	  had	  a	  5%	  decrease	  in	  methylation	  level	  of	  the	  same	  
region	  in	  IGF2,	  measured	  in	  adulthood.	  The	  results	  were	  significant	  for	  the	  same	  
CpGs	  in	  both	  preterm	  infants	  who	  were	  appropriate	  for	  gestational	  age	  (AGA)	  
and	  SGA.	  	  
Study	  III	  
Genome-­‐wide	  analysis	  of	  methylation	  data	  in	  UPD(7)	  
The	  aim	  of	  Study	  III	  was	  to	  use	  a	  genome-­‐wide	  methylation	  assay	  to	  study	  the	  
methylation	  differences	  between	  UPD(7)mat	  patients,	  controls	  and	  a	  rare	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UPD(7)pat	  sample	  in	  order	  to	  identify	  new	  differentially	  methylated	  regions	  
(DMRs)	  and	  imprinted	  genes	  on	  chromosome	  7.	  Since	  maternal	  and	  paternal	  
alleles	  of	  imprinted	  genes	  are	  differentially	  methylated	  at	  DMRs,	  comparing	  
UPD(7)mat	  and	  UPD(7)pat	  samples	  with	  controls	  should	  indicate	  regions	  where	  
uniparental	  disomies	  cause	  significantly	  higher	  or	  lower	  levels	  of	  methylation	  
compared	  to	  control	  samples.	  Initial	  genome-­‐wide	  analysis	  indicated	  that	  the	  
significantly	  differentially	  methylated	  regions	  (genome-­‐wide	  significance	  
threshold,	  p=5	  x	  10-­‐8)	  between	  UPD(7)mat	  patients	  and	  controls	  were	  located	  
exclusively	  on	  chromosome	  7,	  as	  expected.	  A	  similar	  pattern	  was	  observed	  in	  
differentially	  methylated	  CpGs	  between	  UPD(7)pat	  vs.	  controls	  clustering	  on	  
chromosome	  7.	  These	  results	  confirmed	  that	  the	  approach	  was	  useful	  in	  
highlighting	  genomic	  locations	  where	  DMRs	  were	  affected	  by	  uniparental	  
disomy,	  and	  the	  study	  then	  proceeded	  with	  targeting	  chromosome	  7	  only.	  
Differentially	  methylated	  regions	  on	  chromosome	  7	  	  
The	  analysis	  of	  chromosome	  7	  included	  30,017	  CpG	  sites.	  The	  filtering	  approach	  
was	  able	  to	  pinpoint	  DMRs	  of	  already	  known	  imprinted	  genes	  on	  chromosome	  7;	  
GRB10	  (7p12.2),	  SGCE/PEG10	  (sarcoglycan	  epsilon/paternally	  expressed	  10,	  at	  
7q21.3)	  and	  MEST/MESTIT1	  (mesoderm	  specific	  transcript/MEST	  intronic	  
transcript	  1,	  antisense	  RNA,	  at	  7q32),	  confirming	  that	  the	  approach	  was	  useful	  in	  
finding	  DMRs	  of	  imprinted	  genes.	  DMRs	  were	  also	  found	  for	  the	  two	  previously	  
predicted	  imprinted	  genes,	  HOXA4	  (7p15.2)	  and	  GLI3	  (GLI	  family	  zinc	  finger	  3,	  at	  
7p13),	  as	  well	  as	  for	  PON1	  (paraoxonase	  1,	  at	  7q21.3),	  a	  disputed	  imprinted	  
gene.	  Other	  found	  DMRs	  were	  located	  near	  eight	  genes	  [MAD1L1	  (mitotic	  arrest	  
deficient	  1	  like	  1,	  at	  7p22),	  CARD11	  (caspase	  recruitment	  domain	  family	  member	  
11,	  at	  7p22),	  RPS2P32	  (ribosomal	  protein	  S2	  pseudogene,	  at	  7p15.3),	  PRR15	  
(proline	  rich	  15,	  at	  7p14.3),	  SH2B2	  (SH2B	  adaptor	  protein	  2,	  at	  7q22),	  SVOPL	  
(SVOP	  like,	  at	  7q34),	  HTR5A	  (5-­‐hydroxytryptamine	  receptor	  5A,	  at	  7q36.1)	  and	  
RARRES2	  (retinoic	  acid	  receptor	  responder	  2,	  at	  7q36.1]	  and	  two	  intergenic	  
regions	  with	  lncRNAs.	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Validation	  of	  methylation	  status	  with	  pyrosequencing	  	  
In	  order	  to	  test	  whether	  the	  methylation	  results	  could	  be	  replicated	  by	  using	  
another	  methylation	  assay,	  CpG	  sites	  of	  HTR5A	  and	  HOXA4	  were	  studied	  by	  
pyrosequencing.	  There	  was	  a	  high	  correlation	  (94-­‐95%)	  of	  methylation	  levels	  of	  
corresponding	  CpG	  sites	  obtained	  by	  the	  Infinium	  HumanMethylation450K	  
BeadChip	  and	  pyrosequencing,	  indicating	  reliability	  of	  the	  results.	  	  
Differentially	  expressed	  genes	  on	  chromosome	  7	  	  
After	  detecting	  DMRs,	  qPCR	  was	  used	  in	  order	  to	  verify	  possible	  imprinted	  
expression	  in	  blood.	  The	  known	  imprinted	  gene	  PEG10	  was	  used	  as	  a	  reference	  
for	  imprinted	  expression	  and	  a	  statistically	  significant	  (p=0.0017)	  difference	  was	  
observed	  between	  expression	  level	  of	  PEG10	  in	  UPD(7)mat	  and	  controls.	  PEG10	  
also	  showed	  a	  pattern	  of	  expression	  that	  would	  be	  expected	  for	  an	  imprinted	  
gene;	  average	  expression	  of	  controls	  was	  in	  the	  middle	  and	  UPD(7)mat	  and	  
UPD(7)pat	  deviated	  in	  opposite	  directions.	  HOXA4,	  GLI3	  and	  SVOPL	  showed	  a	  
statistically	  significant	  difference	  between	  expression	  level	  of	  UPD(7)mat	  and	  
controls	  (p-­‐values	  0.008,	  0.049	  and	  0.017,	  respectively).	  Also	  the	  general	  pattern	  
of	  expression	  was	  similar	  to	  PEG10.	  For	  some	  of	  the	  studied	  genes,	  a	  pattern	  
suggestive	  of	  imprinted	  expression	  was	  observed,	  but	  the	  differences	  between	  
UPD(7)mat	  and	  controls	  were	  not	  statistically	  significant.	  For	  others,	  expression	  
levels	  did	  not	  suggest	  imprinting.	  For	  HTR5A	  and	  PON1,	  expression	  in	  blood	  was	  
not	  detected,	  so	  it	  was	  not	  possible	  to	  carry	  out	  further	  studies.	  Expression	  levels	  
of	  genes	  located	  close	  to	  the	  intergenic	  regions	  with	  detected	  DMRs	  were	  not	  
studied.	  	  
Parent-­‐of-­‐origin	  allele-­‐specific	  expression	  analysis	  
Allele-­‐specific	  expression	  analysis	  was	  conducted	  in	  order	  to	  confirm	  parent-­‐of-­‐
origin	  specific	  expression.	  Exonic	  SNPs	  of	  parent-­‐child	  trios	  of	  the	  tree	  genes	  
with	  differential	  expression;	  HOXA4,	  SVOPL	  and	  GLI3,	  were	  studied.	  In	  order	  to	  
determine	  expression	  from	  a	  single	  parental	  allele,	  it	  was	  required	  to	  find	  exonic	  
SNPs	  for	  which	  the	  child	  is	  heterozygous	  and	  preferably	  both	  parents	  
homozygous	  for	  a	  different	  allele.	  For	  SVOPL,	  two	  trios	  were	  found	  and	  both	  of	  
them	  showed	  expression	  of	  only	  the	  maternal	  allele	  (Figure	  8).	  This	  confirmed	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maternal	  expression	  of	  SVOPL,	  as	  suggested	  by	  the	  previous	  expression	  results	  of	  
UPD(7)mat	  compared	  to	  controls.	  For	  HOXA4,	  one	  heterozygous	  SNP	  was	  found	  
and	  cDNA	  sequencing	  confirmed	  monoallelic	  expression.	  As	  both	  parents	  were	  
heterozygous,	  it	  was	  not	  possible	  to	  determine	  which	  parental	  allele	  was	  
expressed,	  but	  monoallelic	  expression	  supports	  imprinted	  status	  of	  the	  gene.	  For	  






Figure	  8.	  SNP	  rs2305816	  at	  SVOPL	  for	  a	  parent-­‐child	  trio.	  Both	  mother	  and	  father	  
are	  homozygous	  for	  different	  alleles,	  the	  child	  is	  therefore	  heterozygous	  A/C,	  but	  
only	  the	  mother’s	  allele	  A	  is	  expressed	  in	  the	  child.	  Modified	  from	  Hannula-­‐
Jouppi	  et	  al.,	  2014.	  	  
	  
Taken	  together,	  10	  novel	  DMRs	  were	  found	  in	  chromosome	  7,	  two	  DMRs	  for	  the	  
predicted	  imprinted	  genes	  HOXA4	  and	  GLI3	  and	  one	  DMR	  for	  a	  disputed	  
imprinted	  gene	  PON1.	  Differential	  expression	  was	  confirmed	  for	  HOXA4,	  GLI3	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and	  SVOPL	  in	  blood.	  SVOPL	  was	  further	  found	  to	  be	  expressed	  only	  from	  the	  
maternal	  chromosome	  by	  allele-­‐specific	  parent-­‐of-­‐origin	  expression	  analysis.	  
HOXA4	  was	  found	  to	  have	  monoallelic	  expression,	  supporting	  its	  imprinted	  
status.	  	  
	  
HOXA4	  belongs	  to	  a	  cluster	  of	  homeobox-­‐containing	  transcription	  factors	  that	  
control	  the	  anterior-­‐posterior	  patterning	  during	  development	  (Lewis,	  1992).	  
GLI3	  is	  a	  transcription	  factor	  that	  affects	  tissue	  patterning	  and	  its	  defects	  cause	  
multiple	  anomalies	  especially	  involving	  the	  digits	  (Crapster	  et	  al.,	  2017).	  
As	  for	  SVOPL,	  methylation	  changes	  have	  been	  reported	  in	  
pseudohypoparathyroidism	  patients	  with	  multi-­‐locus	  imprinting	  defects	  
(Rochtus	  et	  al.,	  2016).	  The	  observed	  changes	  in	  the	  expression	  levels	  of	  these	  
genes	  in	  UPD(7)mat	  patients	  may	  have	  functional	  consequences	  affecting	  the	  
phenotype	  of	  the	  patients.	  	  
	  
Study	  IV	  
Common	  epigenetic	  changes	  in	  different	  SRS	  subgroups	  	  
The	  objective	  of	  Study	  IV	  was	  to	  use	  a	  genome-­‐wide	  methylation	  array	  to	  look	  for	  
common	  DNA	  methylation	  changes	  shared	  among	  the	  three	  subgroups	  of	  SRS	  
[UPD(7)mat,	  11p15	  LOM	  and	  clinical	  SRS].	  Although	  there	  are	  differences	  
between	  the	  clinical	  characteristics	  of	  the	  three	  subgroups,	  major	  features,	  such	  
as	  growth	  restriction,	  are	  shared	  by	  the	  patients.	  It	  was	  hypothesized	  that	  the	  
subgroups	  may	  share	  common	  DNA	  methylation	  changes	  that	  could	  be	  found	  
using	  a	  genome-­‐wide	  array.	  As	  DMRs	  of	  imprinted	  genes	  often	  involve	  longer	  
stretches	  of	  CpGs,	  the	  strategy	  was	  to	  devise	  a	  filtering	  system	  that	  would	  allow	  
identification	  of	  longer	  stretches	  of	  CpGs.	  	  
	  
Stretches	  of	  consecutive	  CpGs	  were	  found	  differentially	  methylated	  in	  all	  SRS	  
subgroups	  in	  26	  genes	  or	  intergenic	  loci	  on	  13	  different	  chromosomes.	  For	  most	  
of	  these	  loci,	  the	  median	  methylation	  differences	  between	  controls	  and	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subgroups	  were	  small	  (less	  than	  2%).	  Only	  two	  separate	  loci	  included	  CpG	  sites	  
with	  median	  methylation	  differences	  greater	  than	  5%	  between	  controls	  and	  all	  
three	  subgroups,	  an	  intergenic	  region	  at	  5p15.33	  and	  HOXA4.	  The	  region	  at	  
HOXA4	  included	  altogether	  12	  consecutive	  CpG	  sites	  with	  significant	  methylation	  
differences	  between	  controls	  and	  all	  of	  the	  subgroups,	  and	  an	  additional	  stretch	  
of	  3	  CpGs	  with	  similar	  differences.	  HOXA4	  was	  therefore	  selected	  as	  a	  clear	  




Table	  3.	  P-­‐values	  for	  differential	  methylation	  between	  each	  of	  the	  SRS	  subgroups	  
and	  controls	  for	  all	  HOXA4	  CpGs	  of	  the	  Illumina	  450K	  BeadChip	  assay	  that	  passed	  
quality	  control.	  P-­‐values	  <0,05	  are	  highlighted	  in	  red.	  Modified	  from	  Muurinen	  et	  
al.	  2017.	  	  
	  
For	  most	  of	  the	  CpGs,	  the	  hypomethylation	  of	  HOXA4	  was	  strongest	  for	  
UPD(7)mat	  patients	  and	  weakest	  for	  11p15	  patients.	  UPD(7)mat	  itself	  may	  





cg02022102& 0,1337& 0,3379& 0,0345&
cg03982801& 0,4355& 0,2119& 0,8381&
cg02706018& 0,9538& 0,3056& 0,5738&
cg09574499& 0,8489& 0,2095& 0,4154&
cg14042889& 0,6536& 0,8850& 0,6749&
cg11532431& 0,0011$ 0,0013$ 8,2E@06$
cg00562553& 0,0052$ 0,0037$ 0,0002$
cg22997113& 0,0006$ 0,0001$ 1,5E@06$
cg04317399& 0,0309$ 0,0030$ 4,1E@05$
cg07317062& 0,0073$ 0,0014$ 8,4E@06$
cg19142026& 0,0061$ 0,0005$ 7,3E@06$
cg11410718& 0,0037$ 0,0004$ 3,3E@06$
cg17457637& 0,0349$ 0,0011$ 1,4E@05$
cg06942814& 0,0116$ 0,0004$ 1,9E@05$
cg08657492& 0,0063$ 0,0001$ 4,4E@06$
cg04321618& 0,0172$ 0,0009$ 9,7E@06$
cg14359292& 0,0125$ 0,0001$ 9,8E@07$
cg25952581& 0,0818& 0,0125& 0,0002&
cg24169822& 0,0120$ 0,0005$ 5,4E@06$
cg17591595& 0,0371$ 0,0006$ 0,0033$
cg11908057& 0,0108$ 0,0001$ 0,0031$
cg25967031& 0,0804& 0,0035& 0,0167&
cg15196806& 0,0526& 0,0173& 0,0674&
cg15624376& 0,8751& 0,8147& 0,2402&
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UPD(7)mat	  patient	  who	  was	  not	  at	  all	  hypomethylated	  at	  HOXA4	  and	  another	  
UPD(7)mat	  patient	  with	  hypomethylation	  only	  at	  three	  HOXA4	  sites.	  The	  
hypomethylation	  of	  11p15	  LOM	  patients	  may	  be	  explained	  by	  multi-­‐locus	  
imprinting	  disturbance	  (MLID).	  	  
	  
Localization	  of	  the	  CpG	  with	  lowest	  methylation	  levels	  in	  subgroups	  relative	  to	  
the	  controls	  was	  close	  (within	  5-­‐17	  bp)	  to	  the	  TSS,	  which	  suggested	  that	  the	  
found	  methylation	  change	  might	  have	  relevance	  in	  controlling	  expression	  level	  of	  
HOXA4.	  	  	  
	  
	  
Table	  4.	  Average	  height	  and	  weight	  data	  of	  SRS	  and	  SGR	  patients	  in	  Study	  IV.	  	  
	  
Targeted	  study	  of	  HOXA4	  with	  EpiTYPER	  
EpiTYPER	  assay	  was	  used	  for	  a	  targeted	  study	  of	  the	  methylation	  of	  HOXA4	  
promoter	  region.	  One	  EpiTYPER	  CpG	  site,	  cg04317399	  at	  chr7:27170313,	  was	  
also	  covered	  by	  the	  Illumina	  450K	  array	  and	  showed	  a	  strong	  correlation	  
(R2=0.86)	  between	  the	  two	  methods.	  Additional	  three	  CpG	  sites	  covered	  by	  
EpiTYPER	  showed	  similar	  results	  for	  the	  SRS	  patients	  as	  the	  450K	  study,	  
validating	  the	  previous	  results	  of	  HOXA4	  hypomethylation	  at	  the	  promoter	  
region	  in	  SRS	  patients.	  	  
	  
Additionally,	  39	  severely	  growth	  restricted	  children	  were	  included	  in	  a	  targeted	  
study	  to	  find	  out	  whether	  HOXA4	  hypomethylation	  could	  be	  present	  in	  children	  







11p15,LOM, D4,9, D4,0, D4,4,
clinical,SRS, D3,8, D3,4, D3,6,
UPD(7)mat, D3,4, D2,9, D4,8,
UPD(7q21Dqter)mat, D5,2, D4,5, D3,0,
SGR, D3,3, D2,6, D3,8,
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patients	  were	  significantly	  differentially	  methylated	  compared	  to	  controls	  at	  all	  
four	  studied	  sites.	  Analysis	  of	  individual	  patients	  showed	  that	  44%	  of	  the	  SGR	  
patients	  were	  hypomethylated	  in	  at	  least	  two-­‐thirds	  of	  the	  probes	  at	  HOXA4	  
promoter	  region.	  The	  largest	  difference	  (I-­‐J=-­‐0.249,	  p	  =	  3.389	  x	  10-­‐7)	  between	  
subjects	  and	  controls	  was	  found	  for	  clinical	  SRS	  (I)	  compared	  to	  controls	  (J).	  The	  
targeted	  study	  therefore	  revealed	  that	  HOXA4	  hypomethylation	  was	  not	  limited	  







Figure	  9.	  Methylation	  levels	  measured	  at	  EpiTYPER	  CpG	  unit	  
HOXA4F6CpG12.13.14	  with	  the	  largest	  difference	  between	  clinical	  SRS	  patients	  
and	  controls.	  Modified	  from	  Muurinen	  et	  al.,	  2017.	  	  
	   	  
p = 1.43 x 10-4
p = 2 x 10-6
p = 3.41 x 10-7
p = 1 x 10-6
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Frequency	  of	  11p15	  LOM	  higher	  than	  previously	  tested	  	  
During	  preliminary	  analysis	  of	  the	  450K	  methylation	  study,	  it	  became	  evident	  
that	  more	  patients	  had	  11p15	  LOM	  than	  had	  been	  previously	  identified	  with	  a	  
restriction	  site-­‐specific	  methylation	  method	  (Bruce	  et	  al.,	  2008).	  An	  area	  with	  36	  
CpG	  sites	  was	  tested	  and	  a	  patient	  was	  considered	  hypomethylated	  when	  at	  least	  
two-­‐thirds	  of	  the	  CpGs	  were	  hypomethylated	  (below	  -­‐2	  SD	  of	  the	  controls).	  The	  
results	  were	  similar	  to	  those	  published	  in	  another	  genome-­‐wide	  methylation	  
study,	  where	  Infinium	  Human	  Methylation	  450K	  BeadChip	  array	  detected	  more	  
SRS	  patients	  with	  11p15	  LOM	  than	  methylation-­‐sensitive	  RFLP	  (restriction	  
fragment	  length	  polymorphism)	  PCR	  method	  (Prickett	  et	  al.	  2015).	  Genome-­‐
wide	  arrays	  may	  therefore	  be	  more	  sensitive	  at	  detecting	  methylation	  changes	  
than	  some	  of	  the	  other	  methods.	  	  
Correlation	  of	  HOXA4	  methylation	  level	  with	  height	  in	  healthy	  children	  
Since	  HOXA4	  promoter	  hypomethylation	  was	  present	  in	  both	  SRS	  and	  SGR	  
patients,	  the	  next	  step	  was	  to	  study	  whether	  HOXA4	  methylation	  level	  was	  
associated	  with	  height	  in	  healthy	  children.	  Illumina	  450K	  BeadChip	  methylation	  
data	  from	  227	  children	  was	  used	  to	  study	  the	  correlation	  of	  methylation	  level	  of	  
HOXA4	  promoter	  with	  relative	  height	  at	  school	  age.	  Both	  height	  measurements	  
and	  DNA	  samples	  for	  methylation	  testing	  had	  been	  taken	  at	  approximately	  8	  
years	  of	  age.	  In	  order	  to	  make	  the	  height	  measurements	  comparable	  to	  each	  
other,	  the	  height	  of	  each	  individual	  was	  converted	  to	  SD	  scale.	  The	  results	  
showed	  that	  the	  height	  of	  the	  children	  correlated	  with	  methylation	  level	  at	  
multiple	  sites	  of	  the	  HOXA4	  promoter	  region,	  for	  example	  at	  cg11908057	  at	  age	  
eight	  (r=0.148,	  n=225,	  p=0.026).	  Next,	  the	  correlation	  between	  height	  at	  age	  
eight	  and	  genotypes	  of	  some	  the	  most	  strongly	  height-­‐associated	  SNPs	  were	  
studied	  in	  the	  same	  individuals.	  No	  significant	  association	  was	  found	  between	  
height	  and	  genotype.	  Therefore,	  in	  the	  dataset	  of	  healthy	  children,	  the	  
methylation	  level	  of	  cg11908057	  at	  HOXA4	  was	  better	  at	  explaining	  height	  
variation	  at	  school-­‐age	  than	  some	  of	  the	  best	  height-­‐associated	  SNPs.	  
Interestingly,	  cg11908057	  is	  located	  in	  a	  potential	  regulatory	  protein-­‐binding	  
site	  for	  an	  enhancer	  of	  zeste	  homolog	  2	  (EZH2),	  which	  is	  a	  methyltransferase	  
enzyme	  encoded	  by	  the	  EZH2	  gene	  on	  7q36.1.	  EZH2	  is	  implicated	  in	  Weaver	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syndrome,	  a	  rare	  congenital	  syndrome	  characterized	  by	  pre-­‐	  and	  postnatal	  
overgrowth	  and	  tall	  adult	  stature	  (Gibson	  et	  al.,	  2012)	  
Correlation	  of	  methylation	  level	  of	  HOXA4	  promoter	  with	  expression	  of	  
HOXA4	  
As	  the	  hypomethylated	  area	  of	  HOXA4	  was	  located	  at	  the	  promoter	  region,	  the	  
next	  step	  was	  to	  study	  whether	  methylation	  level	  of	  the	  promoter	  region	  
correlated	  with	  the	  expression	  level	  of	  the	  HOXA4	  gene	  in	  blood.	  As	  expression	  
level	  of	  HOXA4	  had	  already	  been	  measured	  in	  Study	  III	  to	  verify	  imprinted	  
expression,	  it	  was	  possible	  to	  use	  the	  same	  data	  for	  Study	  IV	  in	  order	  to	  study	  the	  
correlation	  between	  methylation	  level	  of	  HOXA4	  promoter	  and	  expression	  in	  
UPD(7)mat,	  UPD(7)pat	  and	  controls.	  Statistically	  significant	  negative	  correlation	  
was	  observed	  between	  methylation	  level	  and	  expression	  in	  all	  differentially	  
methylated	  HOXA4	  CpGs.	  cg22997113	  showed	  the	  strongest	  negative	  correlation	  
(r=-­‐0.81,	  n=20,	  p=1.40	  x	  10-­‐5).	  The	  results	  suggested	  that	  DNA	  methylation	  level	  




Figure	  10.	  HOXA4	  expression	  level	  in	  blood	  vs.	  methylation	  level	  of	  HOXA4	  
cg11532431.	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Taken	  together,	  this	  study	  demonstrated	  a	  methylation	  change	  shared	  by	  
UPD(7)mat,	  11p15	  LOM	  and	  clinical	  SRS	  patients.	  The	  HOXA4	  promoter	  region	  
hypomethylation	  was	  present	  in	  55%	  of	  the	  SRS	  patients	  and	  targeted	  studies	  of	  
the	  region	  revealed	  that	  it	  was	  also	  present	  in	  44%	  of	  patients	  with	  SGR.	  A	  
statistically	  significant	  negative	  correlation	  was	  demonstrated	  between	  HOXA4	  
expression	  and	  promoter	  methylation	  level	  in	  blood.	  In	  further	  analysis,	  it	  was	  
found	  that	  HOXA4	  promoter	  methylation	  level	  was	  correlated	  with	  height	  in	  
healthy	  children	  and	  the	  effect	  size	  was	  larger	  than	  for	  any	  of	  the	  nine	  tested	  
highly	  significant	  height-­‐associated	  SNPs.	  	  
	  
The	  HOXA4	  gene	  is	  located	  on	  7p15.2,	  in	  a	  cluster	  of	  HOXA	  genes.	  Multiple	  HOXA	  
genes	  have	  been	  predicted	  to	  be	  maternally	  expressed	  imprinted	  genes	  (Luedi	  et	  
al.,	  2007).	  HOX	  genes	  are	  also	  highly	  conserved	  across	  species.	  Mouse	  Hoxa4	  
loss-­‐of-­‐function	  homozygous	  mutants	  have	  skeletal	  abnormalities	  including	  
partial	  anterior	  transformation	  of	  C3,	  posterior	  transformations	  of	  C7	  to	  T1,	  
presence	  of	  C7	  cervical	  rib	  and	  malformation	  of	  the	  sternum	  (Horan	  et	  al.,	  
1994)(Kostic	  &	  Capecchi,	  1994).	  Mutations	  of	  the	  human	  HOX	  genes	  cause	  
phenotypes	  such	  as	  facial	  dysmorphisms,	  various	  limb	  and	  digit	  anomalies,	  
cardiac	  defects	  and	  urogenital	  malformations	  (Quinonez	  &	  Innis,	  2014).	  The	  
known	  functions	  of	  HOX	  and	  Hoxa4	  genes	  suggest	  that	  altered	  expression	  levels	  
of	  HOXA4	  may	  also	  have	  relevance	  regarding	  skeletal	  malformations	  in	  SRS.	  
Upregulation	  of	  several	  HOX	  genes	  has	  also	  been	  reported	  in	  3-­‐M	  syndrome	  
(Murray	  et	  al.,	  2013),	  a	  growth	  restriction	  syndrome	  with	  a	  similar	  phenotype	  to	  
SRS.	  An	  association	  between	  birth	  weight	  and	  methylation	  level	  of	  two	  CpGs	  has	  
been	  observed	  in	  HOXA3,	  the	  gene	  adjacent	  to	  HOXA4	  (Simpkin	  et	  al.,	  2015),	  
demonstrating	  that	  the	  region	  may	  play	  a	  role	  in	  regulating	  body	  size.	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Limitations	  of	  the	  studies	  	  
	  
	  
The	  studies	  in	  this	  thesis	  utilize	  genome-­‐wide	  approaches	  in	  order	  to	  search	  for	  
new	  variants	  contributing	  to	  SRS	  and	  growth	  restriction.	  Both	  genotyping	  arrays	  
and	  genome-­‐wide	  methylation	  arrays	  are	  limited	  by	  the	  number	  of	  probes	  they	  
contain	  and	  the	  array	  design	  that	  determines	  the	  distribution	  of	  the	  probes	  
across	  the	  genome.	  Therefore	  some	  true	  genetic/epigenetic	  changes	  are	  
probably	  left	  undetected	  by	  these	  studies.	  Quality	  control	  steps	  further	  reduce	  
the	  number	  of	  informative	  sites	  for	  analysis,	  such	  as	  the	  reduction	  of	  CpG	  sites	  
from	  over	  450	  000	  to	  361	  950	  after	  quality	  control	  in	  Study	  IV.	  	  
	  
The	  genome-­‐wide	  methylation	  studies	  are	  especially	  affected	  by	  the	  design	  of	  the	  
filtering	  approach.	  It	  is	  possible	  that	  single	  CpG	  sites	  on	  the	  array	  would	  have	  
been	  relevant,	  but	  in	  the	  approaches	  used	  in	  Study	  III	  and	  Study	  IV,	  they	  were	  
filtered	  out.	  Study	  IV	  is	  also	  affected	  by	  the	  chosen	  approach	  to	  look	  for	  
methylation	  changes	  common	  to	  all	  SRS	  subgroups.	  Another	  type	  of	  approach,	  
targeting	  single	  groups	  or	  cases,	  would	  have	  given	  very	  different	  results.	  	  
	  
Sample	  size	  is	  a	  common	  limiting	  factor	  in	  studies	  of	  rare	  diseases,	  such	  as	  SRS.	  
Limited	  sample	  size	  was	  especially	  apparent	  in	  Study	  III,	  with	  only	  eight	  
UPD(7)mat	  samples,	  one	  UPD(7q31-­‐qter)mat	  sample	  and	  one	  UPD(7)pat	  
sample.	  However,	  these	  extremely	  rare	  samples	  enabled	  the	  study	  of	  DMRs	  of	  
chromosome	  7	  in	  a	  unique	  way,	  and	  the	  small	  sample	  size	  is	  therefore	  justified.	  
There	  are	  only	  a	  handful	  of	  UPD(7)pat	  cases	  reported	  in	  literature,	  and	  obtaining	  
more	  samples	  would	  not	  have	  been	  possible.	  	  
	  
In	  Study	  IV,	  16	  control	  samples	  were	  used	  to	  calculate	  normal	  levels	  of	  
methylation	  that	  was	  then	  compared	  to	  the	  methylation	  level	  of	  the	  patients.	  A	  
larger	  number	  of	  control	  samples	  would	  have	  improved	  the	  accuracy	  of	  
establishing	  a	  normal	  methylation	  level.	  	  
	  
Study	  II	  would	  have	  also	  benefited	  from	  a	  larger	  sample	  size.	  Although	  the	  
results	  were	  interesting	  and	  concordant	  with	  other	  studies,	  it	  was	  not	  possible	  to	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assess	  whether	  a	  2%	  methylation	  level	  difference	  in	  a	  CpG	  site	  of	  IGF2	  would	  
have	  clinical	  relevance.	  	  
	  
Methylation	  levels	  of	  imprinted	  loci	  have	  been	  shown	  to	  vary	  between	  tissues	  of	  
a	  single	  individual.	  The	  studies	  in	  this	  thesis	  are	  limited	  to	  observations	  of	  
methylation	  levels	  in	  blood	  and	  may	  not	  reflect	  the	  status	  in	  other	  tissues	  that	  
may	  be	  more	  relevant	  for	  growth.	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CONCLUSIONS	  AND	  FUTURE	  PROSPECTS	  	  
	  
Studies	  I,	  III	  and	  IV	  demonstrated	  the	  usefulness	  of	  genome-­‐wide	  arrays	  in	  both	  
genetic	  and	  epigenetic	  studies	  of	  a	  rare	  imprinting	  disorder.	  Due	  to	  the	  
heterogeneous	  etiology	  of	  SRS,	  untargeted	  genome-­‐wide	  arrays	  are	  especially	  
useful	  in	  finding	  molecular	  aberrations	  for	  single	  patients	  (Study	  I)	  as	  well	  as	  
groups	  of	  patients	  (Study	  IV).	  Genome-­‐wide	  methylation	  arrays	  can	  also	  be	  
tailored	  for	  specific	  purposes,	  such	  as	  finding	  certain	  types	  of	  DNA	  methylation	  
patterns	  by	  creating	  filtering	  systems	  (Studies	  III	  and	  IV).	  	  
	  
Atypical	  clinical	  presentation	  in	  syndromic	  patients,	  such	  as	  the	  SRS-­‐like	  patients	  
in	  Study	  I,	  complicates	  making	  a	  diagnosis	  and	  therefore	  targeted	  studies	  may	  
not	  always	  lead	  to	  finding	  the	  underlying	  molecular	  abnormality.	  In	  such	  cases,	  
genome-­‐wide	  arrays	  may	  prove	  to	  be	  especially	  useful,	  and	  may	  lead	  to	  detection	  
of	  an	  alternative	  diagnosis.	  An	  example	  of	  this	  was	  the	  finding	  of	  an	  IGF2R	  
deletion	  in	  a	  SRS-­‐like	  patient	  (Study	  I),	  who	  presented	  with	  relative	  
macrocephaly,	  a	  clinical	  feature	  very	  typical	  of	  SRS	  patients,	  instead	  of	  
microcephaly	  that	  is	  usually	  seen	  in	  IGF2R	  deletion	  patients.	  	  	  
	  
Imprinted	  genes,	  in	  particular,	  may	  be	  sensitive	  to	  environmental	  influences	  and	  
the	  association	  between	  epigenetic	  changes	  of	  imprinted	  genes	  and	  
environmental	  influences	  has	  been	  demonstrated	  in	  many	  studies.	  Study	  II	  and	  
the	  Dutch	  famine	  study	  both	  demonstrate	  lower	  methylation	  levels	  of	  IGF2	  CpG	  
sites	  in	  individuals	  with	  early	  adverse	  events	  (VLBW	  pre-­‐term	  born	  individuals	  
in	  Study	  II	  and	  early	  caloric	  restriction	  in	  the	  Dutch	  famine	  study)	  and	  later	  risk	  
of	  adult-­‐onset	  disease.	  Altered	  methylation	  level	  at	  IGF2	  therefore	  might	  provide	  
a	  potential	  mechanism	  for	  later	  disease	  risk	  development.	  This	  mechanism	  for	  
the	  origin	  of	  adult-­‐onset	  disease	  may	  be	  confirmed	  in	  future	  studies.	  
	  
The	  causative	  imprinted	  genes	  on	  chromosome	  7	  for	  SRS	  in	  UPD(7)mat	  patients	  
are	  not	  known.	  Study	  III	  was	  able	  to	  provide	  a	  picture	  of	  the	  methylation	  
landscape	  of	  chromosome	  7	  in	  regions	  where	  methylation	  levels	  are	  affected	  by	  
parental	  origin.	  These	  regions	  may	  indicate	  regions	  potentially	  responsible	  for	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the	  SRS	  phenotype.	  In	  addition	  to	  differences	  in	  methylation,	  HOXA4,	  GLI3	  and	  
SVOPL	  were	  found	  to	  have	  expression	  differences,	  suggesting	  imprinted	  
expression	  of	  these	  genes	  in	  blood.	  Lack	  of	  differential	  expression	  for	  some	  of	  the	  
other	  genes	  in	  blood	  does	  not	  rule	  out	  imprinting	  in	  other	  tissues.	  Parent-­‐of-­‐
origin	  specific	  expression	  analysis	  also	  confirmed	  SVOPL	  as	  a	  maternally	  
expressed	  imprinted	  gene.	  However,	  little	  is	  known	  about	  the	  function	  of	  SVOPL.	  
HOXA4	  and	  GLI3	  were	  both	  interesting	  findings	  of	  the	  study	  as	  they	  have	  been	  
shown	  to	  have	  important	  roles	  in	  body	  patterning	  during	  development.	  	  
	  
As	  growth	  restriction	  is	  one	  of	  the	  key	  features	  shared	  by	  all	  subgroups	  of	  SRS,	  
Study	  IV	  aimed	  to	  explore	  whether	  a	  common	  epigenetic	  change	  would	  be	  
shared	  by	  the	  SRS	  subgroups.	  A	  clear	  region	  with	  multiple	  adjacent	  
hypomethylated	  CpGs	  was	  found	  in	  the	  promoter	  region	  of	  HOXA4.	  This	  region	  
was	  remarkably	  larger	  in	  size	  and	  with	  greater	  methylation	  differences	  than	  any	  
other	  region	  in	  the	  genome-­‐wide	  screen.	  HOXA4	  hypomethylation	  was	  found	  not	  
to	  be	  specific	  for	  SRS,	  but	  was	  also	  found	  in	  a	  substantial	  proportion	  of	  patients	  
with	  severe	  growth	  restriction	  of	  unknown	  etiology.	  A	  further	  study	  found	  a	  
correlation	  between	  HOXA4	  methylation	  level	  and	  height	  of	  healthy	  school-­‐aged	  
children.	  Study	  IV	  led	  to	  a	  hypothesis	  that	  HOXA4	  may	  play	  a	  role	  in	  regulating	  
pathways	  relevant	  for	  SRS,	  growth	  restriction	  and	  height	  in	  general.	  The	  study	  
suggests	  a	  new	  target	  region	  for	  future	  studies	  in	  SRS,	  imprinting	  and	  growth.	  A	  
better	  understanding	  of	  the	  molecular	  mechanisms	  that	  influence	  SRS	  will	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